The Journal of Clinical Psychiatry

Author Index to Volume 70: January 2009 Through December 2009

Aboujaoude E see Koran LM
Abrams RC, Leon AC, Tardiff K, Marzuk PM, Li C, Galea S. Antidepressant use in elderly suicide victims in New York City: an analysis of 255 cases. Mar 312–317
Adams DH see Lindenmayer J-P
Adamson JJ see Surman CBH
Adler LA, Weisler RH, Goodman DW, Hamdani M, Niebler GE. Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder. Dec 1652–1661
Adler LA. Pharmacotherapy for adult ADHD. May e12
Agerbo E see Laursen TM
Agomelatine Study Group see Goodwin GM
Agoston AM see Mischoulon D
Ahn H see Kim B-N
Aisen PS see Tariot PN
Albala AA see Husain MM
Albanese MJ see Khantzian EJ
Alderman JA see Gandelman K
Allegri RF see Taragano FE
Allen-Dicker K see Soto EC
Alpert JE see Mischoulon D
Altoè G see Moscardino U
Altshuler LL, Post RM, Hellemann G, Leverich GS, Nolen WA, Frye MA, Keck PE, Kupka RW, Grunze H, McElroy SL, Sugar CA, Suppes T. Impact of antidepressant continuation after acute positive or partial treatment response for bipolar depression: a blinded, randomized study. Apr 450–457
Altshuler LL see Suri R
Alvarez-Jimenez M see Gleeson JFM
Amminger GP see McGorry PD
Anand S, Malhi GS. Why *DSM-V* needs to address anger [letter]. Oct 1478–1480
Anbarasan D see Saavedra-Velez C
Ancelin M-L see Ritchie K
Andersen SL see Teicher MH
Anderson GM see Shulman KI
Andersson G see Cuijpers P
Annas P see Hampel H
Arnold LM. Pain and the brain: chronic widespread pain. Apr e10
Arnow B see Kocsis JH
Ascher-Svanum H see Lindenmayer J-P; Stensland MD
Asenjo MA see Scott J
Ash P see Jacob MK
Asnis G see Liebowitz MR
Assunção-Talbott S see Janicak PG; Kane JM
Åström M see Cutler AJ
Athanasiou M see Rickels K
Atkinson L see Levitan RD
Austin KL see Ilgen MA
Austin M-P see Barnett B
Avila M see Nejtek VA
Axelson DA see Romero S
Ayesa R see Crespo-Facorro B
Ayuso-Mateos JL see Sanchez-Moreno J
Azoulay L, Bérard A. Reply to Thakrar BT: Isotretinoin and the risk of depression [letter]. Oct 1475–1476
Baca-Garcia E see Blasco-Fontecilla H
Bailine SH see Rasmussen KG
Baji I, Lopez-Duran NL, Kovacs M, George CJ, Mayer L, Kapornai K, Kiss E, Gádoros J, Vetró Á. Age and sex analyses of somatic complaints and symptom presentation of childhood depression in a Hungarian clinical sample. Oct 1467–1472
Baker RA see Meyer JM
Balan IC see Markowitz JC
Balasubramani GK see Husain MM
Baldessarini RJ see Fawcett JA; Salvatore P; Wingo AP
Ball MP see Kelly DL
Balon R. Review of Makari GJ: *Revolution in Mind: The Creation of Psychoanalysis.* Oct 1481
Baran RW see Kleinman NL
Barnett B, Austin M-P. Reflections on perinatal depression treatment [commentary]. Sept 1315–1316
Barnhill LJ see Fletcher RJ
Barraco A see Benazzi F
Barry DT, Beitel M, Garnet B, Joshi D, Rosenblum A, Schottenfeld RS. Relations among psychopathology, substance use, and physical pain experiences in methadone-maintained patients. Sept 1213–1218
Bartolic EI see Rapaport MH
Barton D. Review of Siegel DJ: *The Mindful Brain: Reflection and Attunement in the Cultivation of Well-Being.* Mar 435–436
Bashir M see Shajahan P
Bastiampillai T see Mohan T
Basun H see Hampel H
Bate A see Karlsson J
Batten LA see Chenu F
Batzar E see Vanderburg DG
Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J, Brecher M. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. Apr 540–549
Bauer MS see Perron BE
Beaumont EC see Mischoulon D
Bechdolf A see McGorry PD
Becker MA. Review of Doran CM: *The Hypomania Handbook: The Challenge of Elevated Mood.* July 1060–1061
Bédard M see Rapoport MJ
Beekman ATF see Wiersma JE
Beitel M see Barry DT
Bejjani C see Lomax JW
Bell MA see Markowitz JC
Bellantuono C see Gentile S
Belmonte-de-Abreu PS see de Lucena D
Benabarre A see Murru A; Sanchez-Moreno J; Scott J
Benazzi F. What is hypomania? tetrachoric factor analysis and kernel estimation of *DSM-IV* hypomanic symptoms. Nov 1514–1521
Benazzi F, Berk M, Frye MA, Wang W, Barraco A, Tohen M. Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis. Oct 1424–1431
Bender RE see Jaffee WB
Benes FM see Nasrallah HA
Benson BA see Fletcher RJ
Bérard A see Azoulay L
Berger G see McGorry PD
Berk M see Benazzi F; de Lucena D; McGorry PD
Bernabei R see Liperoti R
Bernet W. Review of Appelbaum PS, Gutheil TG: *Clinical Handbook of Psychiatry and the Law, 4th ed.* June 941
Bernstein IH see Dennehy EB
Berry-Kravis E see Bourgeois JA
Bian QT see Chen JX
Biederman J, Petty CR, Monuteaux MC, Evans M, Parcell T, Faraone SV, Wozniak J. Child Behavior Checklist-Pediatric Bipolar Disorder profile predicts a subsequent diagnosis of bipolar

The Journal of Clinical Psychiatry

Author Index to Volume 70: January 2009 Through December 2009

Aboujaoude E see Koran LM
Abrams RC, Leon AC, Tardiff K, Marzuk PM, Li C, Galea S. Antidepressant use in elderly suicide victims in New York City: an analysis of 255 cases. Mar 312–317
Adams DH see Lindenmayer J-P
Adamson JJ see Surman CBH
Adler LA, Weisler RH, Goodman DW, Hamdani M, Niebler GE. Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder. Dec 1652–1661
Adler LA. Pharmacotherapy for adult ADHD. May e12
Agerbo E see Laursen TM
Agomelatine Study Group see Goodwin GM
Agoston AM see Mischoulon D
Ahn H see Kim B-N
Aisen PS see Tariot PN
Albala AA see Husain MM
Albanese MJ see Khantzian EJ
Alderman JA see Gandelman K
Allegri RF see Taragano FE
Allen-Dicker K see Soto EC
Alpert JE see Mischoulon D
Altoè G see Moscardino U
Altshuler LL, Post RM, Hellemann G, Leverich GS, Nolen WA, Frye MA, Keck PE, Kupka RW, Grunze H, McElroy SL, Sugar CA, Suppes T. Impact of antidepressant continuation after acute positive or partial treatment response for bipolar depression: a blinded, randomized study. Apr 450–457
Altshuler LL see Suri R
Alvarez-Jimenez M see Gleeson JFM
Amminger GP see McGorry PD
Anand S, Malhi GS. Why *DSM-V* needs to address anger [letter]. Oct 1478–1480
Anbarasan D see Saavedra-Velez C
Ancelin M-L see Ritchie K
Andersen SL see Teicher MH
Anderson GM see Shulman KI
Andersson G see Cuijpers P
Annas P see Hampel H
Arnold LM. Pain and the brain: chronic widespread pain. Apr e10
Arnow B see Kocsis JH
Ascher-Svanum H see Lindenmayer J-P; Stensland MD
Asenjo MA see Scott J
Ash P see Jacob MK
Asnis G see Liebowitz MR
Assunção-Talbott S see Janicak PG; Kane JM
Åström M see Cutler AJ
Athanasiou M see Rickels K
Atkinson L see Levitan RD
Austin KL see Ilgen MA
Austin M-P see Barnett B
Avila M see Nejtek VA
Axelson DA see Romero S
Ayesa R see Crespo-Facorro B
Ayuso-Mateos JL see Sanchez-Moreno J
Azoulay L, Bérard A. Reply to Thakrar BT: Isotretinoin and the risk of depression [letter]. Oct 1475–1476
Baca-Garcia E see Blasco-Fontecilla H
Bailine SH see Rasmussen KG
Baji I, Lopez-Duran NL, Kovacs M, George CJ, Mayer L, Kapornai K, Kiss E, Gádoros J, Vetró Á. Age and sex analyses of somatic complaints and symptom presentation of childhood depression in a Hungarian clinical sample. Oct 1467–1472
Baker RA see Meyer JM
Balan IC see Markowitz JC
Balasubramani GK see Husain MM
Baldessarini RJ see Fawcett JA; Salvatore P; Wingo AP
Ball MP see Kelly DL
Balon R. Review of Makari GJ: *Revolution in Mind: The Creation of Psychoanalysis.* Oct 1481
Baran RW see Kleinman NL
Barnett B, Austin M-P. Reflections on perinatal depression treatment [commentary]. Sept 1315–1316
Barnhill LJ see Fletcher RJ
Barraco A see Benazzi F
Barry DT, Beitel M, Garnet B, Joshi D, Rosenblum A, Schottenfeld RS. Relations among psychopathology, substance use, and physical pain experiences in methadone-maintained patients. Sept 1213–1218
Bartolic EI see Rapaport MH
Barton D. Review of Siegel DJ: *The Mindful Brain: Reflection and Attunement in the Cultivation of Well-Being.* Mar 435–436
Bashir M see Shajahan P
Bastiampillai T see Mohan T
Basun H see Hampel H
Bate A see Karlsson J
Batten LA see Chenu F
Batzar E see Vanderburg DG
Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J, Brecher M. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. Apr 540–549
Bauer MS see Perron BE
Beaumont EC see Mischoulon D
Bechdolf A see McGorry PD
Becker MA. Review of Doran CM: *The Hypomania Handbook: The Challenge of Elevated Mood.* July 1060–1061
Bédard M see Rapoport MJ
Beekman ATF see Wiersma JE
Beitel M see Barry DT
Bejjani C see Lomax JW
Bell MA see Markowitz JC
Bellantuono C see Gentile S
Belmonte-de-Abreu PS see de Lucena D
Benabarre A see Murru A; Sanchez-Moreno J; Scott J
Benazzi F. What is hypomania? tetrachoric factor analysis and kernel estimation of *DSM-IV* hypomanic symptoms. Nov 1514–1521
Benazzi F, Berk M, Frye MA, Wang W, Barraco A, Tohen M. Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis. Oct 1424–1431
Bender RE see Jaffee WB
Benes FM see Nasrallah HA
Benson BA see Fletcher RJ
Bérard A see Azoulay L
Berger G see McGorry PD
Berk M see Benazzi F; de Lucena D; McGorry PD
Bernabei R see Liperoti R
Bernet W. Review of Appelbaum PS, Gutheil TG: *Clinical Handbook of Psychiatry and the Law, 4th ed.* June 941
Bernstein IH see Dennehy EB
Berry-Kravis E see Bourgeois JA
Bian QT see Chen JX
Biederman J, Petty CR, Monuteaux MC, Evans M, Parcell T, Faraone SV, Wozniak J. Child Behavior Checklist-Pediatric Bipolar Disorder profile predicts a subsequent diagnosis of bipolar

disorder and associated impairments in ADHD youth growing up: a longitudinal analysis. May 732–740
Biederman J see Henin A; Surman CBH; Wilens TE
Bilali S see Gao K
Bilali SR see Kemp DE
Binder CE see Ravindran AV
Birmaher B see Romero S
Bishara D see Taylor DM
Black JL III see Rasmussen KG
Blanco C see Markowitz JC
Blasco-Fontecilla H, Baca-Garcia E, Dervic K, Perez-Rodriguez MM, Lopez-Castroman J, Saiz-Ruiz J, Oquendo MA. Specific features of suicidal behavior in patients with narcissistic personality disorder. Nov 1583–1587
Blazer DG. Review of Tsuang MT, Stone WS, Lyons MJ (eds): *Recognition and Prevention of Major Mental and Substance Use Disorders.* July 1060
Bleich A see Zohar J
Blier P see Chenu F
Bloch MH. Review of Abramowitz JS, McKay D, Taylor S (eds): *Clinical Handbook of Obsessive-Compulsive Disorder and Related Problems.* Apr 608–609
Blom MBJ see van der Loos MLM
Boarati MA see Fu-I L
Bockting CLH, Spinhoven P, Wouters LF, Koeter MWJ, Schene AH, DELTA Study Group. Long-term effects of preventive cognitive therapy in recurrent depression: a 5.5-year follow-up study. Dec 1621–1628
Bockting CLH see ten Doesschate MC
Bodnar LM, Wisner KL, Moses-Kolko E, Sit DKY, Hanusa BH. Prepregnancy body mass index, gestational weight gain, and the likelihood of major depressive disorder during pregnancy. Sept 1290–1296
Boggs DL see Kelly DL
Bogstedt A see Hampel H
Bosello R see Favaro A
Bourgeois JA, Coffey SM, Rivera SM, Hessl D, Gane LW, Tassone F, Greco C, Finucane B, Nelson L, Berry-Kravis E, Grigsby J, Hagerman PJ, Hagerman RJ. Review of fragile X premutation disorders: expanding the psychiatric perspective. June 852–862
Bowden CL. Diagnosis and impact of bipolar depression. Sept e32
Brady KL see Gao K
Braff DL see Nasrallah HA
Brandon AR, Shivakumar G, Inrig SJ, Lee SJC, Sadler JZ. Cost of restricting knowledge [commentary]. Sept 1320–1321
Brave Heart MYH see Markowitz JC
Brecher M see Bauer M; Cutler AJ; Newcomer JW
Breier A see Kane JM
Brook RA see Kleinman NL
Brooks JO III see Goldberg JF
Brown CH see Dickerson FB
Brown FW. Review of Agronin ME: *Alzheimer Disease and Other Dementias: A Practical Guide, 2nd ed.* Aug 1195–1196
Brutsche N see Machado-Vieira R
Buchanan RW see Kelly DL
Buckley PF see Lindenmayer J-P
Buis T see Levitan RD
Bürger K see Hampel H
Buttacavoli Sosa S see Markowitz JC
Butters MA see Sheffrin M
Bystritsky A, Kerwin LE, Feusner JD. Preliminary study of fMRI-guided rTMS in the treatment of generalized anxiety disorder: 6-month follow-up [letter]. Mar 431–432
Calabrese JR see Gao K; Goldberg JF; Kemp DE
Campbell GM see Trivedi MH
Capello F see Moscardino U
Caregaro L see Favaro A
Carfagno M see Rapaport MH
Carlson JL see Kryzhanovskaya LA
Carlström E see Fazel S
Carpenter D see Velligan DI
Carpenter LL see Philip NS
Carrieri MP see Roux P
Carson WH see Findling RL; Kane JM
Cartwright S see Peele R
Case BG see Pundiak TM
Case M see Trivedi MH
Caselli RJ see Stonnington CM
Castells X see Cunill R
Castellvi P, Navinés R, Gutierrez F, Jiménez D, Márquez C, Subirà S, Solà R, Martín-Santos R. Pegylated interferon and ribavirin–induced depression in chronic hepatitis C: role of personality. June 817–828. Correction, Dec 1729
Castle D see Gleeson JFM
Castro P see Murru A
Cather C see Freudenreich O
Chan BTM see Lee P
Chan S-C see Lee TMC
Chang H-C, Tang C-H, Tsai S-J, Yen F-C, Su K-P. Long-acting injectable risperidone and hospital readmission: a mirror-image study using a national claim-based database in Taiwan [letter]. Jan 141
Chang K see Findling RL
Chang KD. Diagnosing bipolar disorder in children and adolescents. Nov e41
Charles RA see McCue RE
Chelminski I see Zimmerman M
Chen EYH see McGorry PD
Chen JX, Su YA, Wang SL, Bian QT, Liu YH, Wang N, Yang FD, Haile C, Kosten TR, Zhang XY. Aripiprazole treatment of risperidone-induced hyperprolactinemia [letter]. July 1058–1059
Chen K-P see Lee P
Chen L see Lindenmayer J-P
Chen Y-H see Lin H-C
Chen Y-Y, Chiang H-C, Liao S-C, Lee M-B. Suicide sex ratio: the interaction between mental illness and suicide methods [letter]. Feb 294–295
Chenu F, Batten LA, Zernig G, Ladstaetter E, Hébert C, Blier P. Comparison of pharmacokinetic profiles of brand-name and generic formulations of citalopram and venlafaxine: a crossover study. July 958–966
Chiang H-C see Chen Y-Y
Chiles C. Review of Bezchlibnyk-Butler KZ, Jeffries JJ, Virani AS (eds): *Clinical Handbook of Psychotropic Drugs, 17th revised ed.* Feb 299–300
Chiles C. Review of Myers MF, Gabbard GO: *The Physician as Patient: A Clinical Handbook for Mental Health Professionals.* Apr 607
Cho DY, Lindenmayer J-P. Aripiprazole-induced agitation after clozapine discontinuation: a case report [letter]. Jan 141–143
Cho S-C see Kim B-N
Choi NH see Kim B-N
Chopra K see Levitan RD
Chouinard G see Corruble E
Chouinard V-A see Corruble E
Chua H-C see Lee P
Chung SA see Shen J
Ciranni MA, Kearney TE, Olson KR. Comparing acute toxicity of first- and second-generation antipsychotic drugs: a 10-year, retrospective cohort study. Jan 122–129
Citrome L. Adding lithium or anticonvulsants to antipsychotics for the treatment of schizophrenia: useful strategy or exercise in futility? [ASCP Corner] June 932–933
Citrome L, Jaffe A, Levine J. How dosing of ziprasidone in a state hospital system differs from product labeling. July 975–982
Citrome L, Krakowski M. Impact of ethnicity on metabolic outcomes during treatment with antipsychotics: complexities abound [letter]. Nov 1608–1609
Citrome L see Lindenmayer J-P; Volavka J
Clayton AH see Johannes CB
Cleare AJ see Fekadu A
Coccaro EF, Lee RJ, Kavoussi RJ. Double-blind, randomized, placebo-controlled

trial of fluoxetine in patients with intermittent explosive disorder. May 653–662
Coffey SM see Bourgeois JA
Cohen A see Zohar J
Cohen D, Correll CU. Second-generation antipsychotic–associated diabetes mellitus and diabetic ketoacidosis: mechanisms, predictors, and screening need [ASCP Corner]. May 765–766
Colom F see Martinez-Aran A; Sanchez-Moreno J; Scott J
Conley RR see Kelly DL; Stensland MD
Connor DF see Ford JD
Conroy C see Kemp DE
Constant EL see Bauer M
Cooper SA see Fletcher RJ
Cordes J see Lange-Asschenfeldt C
Cornelius V see Taylor DM
Cornwell J see Smith RC
Corrêa H see Neves FS
Correll CU see Cohen D; Kane, JM; Nasrallah HA; Soto EC
Corruble E, Chouinard V-A, Letierce A, Gorwood PAPM, Chouinard G. Is DSM-IV bereavement exclusion for major depressive episode relevant to severity and pattern of symptoms? a case-control, cross-sectional study. Aug 1091–1097
Cortese BM see Flosnik DL; Moore GJ
Corya SA see Trivedi MH
Coryell WH see Fawcett JA
Cosman KM see Porsteinsson AP
Cotton SM see Gleeson JFM
Courtet P see Ritchie K
Crandall DT see Janicak PG
Crespo-Facorro B, Rodríguez-Sánchez JM, Pérez-Iglesias R, Mata I, Ayesa R, Ramirez-Bonilla M, Martínez-Garcia O, Vázquez-Barquero JL. Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison. May 717–729
Crisp K see Gleeson JFM
Cruz N see Martinez-Aran A; Scott J
Cucchiaro J see Nakamura M
Cuijpers P, Dekker J, Hollon SD, Andersson G. Adding psychotherapy to pharmacotherapy in the treatment of depressive disorders in adults: a meta-analysis. Sept 1219–1229
Cuijpers P, van Straten A, van Oppen P, Andersson G. Reply to Gaudiano BA: Premature conclusions about psychotherapy for dysthymia [letter]. Aug 1188–1189
Culpepper L. Generalized anxiety disorder and medical illness. Suppl 2, 20–24
Culpepper L see Jain R
Cummings MR see Goldstein MZ
Cunill R, Castells X, Simeon D. Relationships between obsessive-compulsive symptomatology and severity of psychosis in schizophrenia: a systematic review and meta-analysis. Jan 70–82
Cutler AJ, Montgomery SA, Feifel D, Lazarus A, Åström M, Brecher M. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. Apr 526–539. Correction, Dec 1729
Daban C see Martinez-Aran A; Sanchez-Moreno J
Dahan LE see Mischoulon D
Davidson JRT. First-line pharmacotherapy approaches for generalized anxiety disorder. Suppl 2, 25–31
Davis JM see Smith RC
Davis L see Husain MM
Davis MF, Miller HS, Nolan PE Jr. Bupropion levels in breast milk for 4 mother-infant pairs: more answers to lingering questions [letter]. Feb 297–298
Degenhardt EK see Houston JP
Degner D see Schneider A
De Hert M see Simon V
Dehning S, Matz J, Riedel M, Kerle IA, Müller N. Symptom exacerbation in Tourette syndrome due to bacterial reinfection [letter]. Nov 1606
Deisenhammer EA, Ing C-M, Strauss R, Kemmler G, Hinterhuber H, Weiss EM. Duration of the suicidal process: how much time is left for intervention between consideration and accomplishment of a suicide attempt? Jan 19–24
de Keyzer HJUEM see van der Loos MLM
Dekker J see Cuijpers P
de Leon J. How should research productivity be assessed in early career psychiatric researchers? research funding versus scientific productivity [letter with reply]. Sept 1327–1328
DELTA Study Group see Bockting CLH
de Lucena D, Fernandes BS, Berk M, Dodd S, Medeiros DW, Pedrini M, Kunz M, Gomes FA, Giglio LF, Lobato MI, Belmonte-de-Abreu PS, Gama CS. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. Oct 1416–1423
Dennehy EB, Schnyer R, Bernstein IH, Gonzalez R, Shivakumar G, Kelly DI, Snow DE, Sureddi S, Suppes T. Safety, acceptability, and effectiveness of acupuncture as an adjunctive treatment for acute symptoms in bipolar disorder. June 897–905
Denys D see Vulink NCC
Dervic K see Blasco-Fontecilla H
Desai RA, Potenza MN. Cross-sectional study of problem and pathological gambling in patients with schizophrenia/schizoaffective disorder. Sept 1250–1257
Desai RA see Grant JE
Desmarais JE, Looper KJ. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. Dec 1688–1697
Detke MJ see Perahia DGS
Dew MA see Sheffrin M
Dhillon R see Mohan T
Diaconu G, Turecki G. Obsessive-compulsive personality disorder and suicidal behavior: evidence for a positive association in a sample of depressed patients. Nov 1551–1556
DiazGranados N see Machado-Vieira R
Díaz-Marsá M, Sánchez S, Rico-Villademoros F, for the ZIP-IIG-79 Study Group. Effectiveness and tolerability of oral ziprasidone in psychiatric inpatients with an acute exacerbation of schizophrenia or schizoaffective disorder: a multicenter, prospective, and naturalistic study. Apr 509–517
Dicker R see Soto EC
Dickerson FB, Kreyenbuhl J, Goldberg RW, Fang L, Medoff D, Brown CH, Dixon L. 5-year follow-up of diabetes knowledge in persons with serious mental illness and type 2 diabetes [letter]. July 1057–1058
Dickinson D see Kelly DL
Dimidjian S, O'Hara MW. Pharmacotherapy or untreated antenatal depression: a false dichotomy [commentary]. Sept 1321–1322
Dittmann RW see Kryzhanovskaya LA
Dixon L see Dickerson FB
Doan JF see Kleinman NL
Docherty JP see Velligan DI
Dodd S see de Lucena D
Dolfin D see Zohar J
Donaldson C see Fekadu A
Dording CM see Mischoulon D
Doreleijers TA see 't Hart-Kerkhoffs LA
Doron M see Zohar J
Dossenbach M see Lee P
Downing K see Ilgen MA
Drevets WC see Moore GJ
Driscoll HC see Sheffrin M
Duczakowski C see Menzin J
Duma SJ see Reger MA
Dunner DL. Review of Stahl SM: *Stahl's Essential Psychopharmacology Online, revised and updated 3rd ed.* Apr 607–608
Dupuy A-M see Ritchie K
Earley WR see Bauer M
Ebenbichler CF see Tschoner A
Ebert MH, Faulkner L, Stubbe DE, Winstead DK. Maintenance of certification in psychiatry [commentary]. May 619–626

Ebert MH, Faulkner L, Stubbe DE, Winstead DK. Maintenance of certification in psychiatry. Oct e39
Edwards SE see Lindenmayer J-P
Einarson A. Influence of the media on women taking antidepressants during pregnancy [commentary]. Sept 1313–1314
Ein-Dor T see Solomon Z
Elhai JD see Ford JD
Elhaj O see Kemp DE
Elizagárate E see Sánchez P
Eller T see Maron E
Elmouchtari A see Weiden PJ
Emsley R see Goodwin GM; Newcomer JW
Engel RR see Lange-Asschenfeldt C
Engl J see Tschoner A
Epstein-Lubow G see Gaudiano BA
Eriksson JW see Newcomer JW
Esposito-Smythers C see Romero S
Eudicone JM see Janicak PG
Eugene MC see Soto EC
Evans M see Biederman J
Evans-Lacko SE, Zeber JE, Gonzalez JM, Olvera RL. Medical comorbidity among youth diagnosed with bipolar disorder in the United States. Oct 1461–1466
Evins AE see Freudenreich O
Ewers M see Hampel H
Ezcurra J see Sánchez P
Fagiolini A, Goracci A. Effects of undertreated chronic medical illnesses in patients with severe mental disorders. Suppl 3, 22–29
Falkai P see Schneider A
Fan X see Freudenreich O
Fang L see Dickerson FB
Farabaugh AH see Mischoulon D
Faraone SV see Biederman J; Surman CBH; Wilens TE
Farrow VA see Sayers SL
Faulkner L see Ebert MH
Fava M. Augmentation and combination strategies for complicated depression. Nov e40
Fava M. Partial responders to antidepressant treatment: switching strategies. July e24
Fava M, Mischoulon D. Folate in depression: efficacy, safety, differences in formulations, and clinical issues. Suppl 5, 12–17
Fava M see Husain MM; Mischoulon D; Weiss AP
Favaro A, Caregaro L, Tenconi E, Bosello R, Santonastaso P. Time trends in age at onset of anorexia nervosa and bulimia nervosa. Dec 1715–1721
Fawcett J. Why aren't MAOIs used more often? [ASCP Corner] Jan 139–140
Fawcett JA, Baldessarini RJ, Coryell WH, Silverman MM, Stein DJ. Defining and managing suicidal risk in patients taking psychotropic medications [commentary]. June 782–789
Fawcett JA, Baldessarini RJ, Coryell WH, Silverman MM, Stein DJ. Definition and management of suicidality in psychiatric patients. Oct e38
Fazel S, Grann M, Carlström E, Lichtenstein P, Långström N. Risk factors for violent crime in schizophrenia: a national cohort study of 13,806 patients. Mar 362–369
Feifel D see Cutler AJ
Fekadu A, Cleare AJ. Reply to Pies RW: Pseudoresistant bipolar depression [letter]. Oct 1476–1477
Fekadu A, Wooderson S, Donaldson C, Markopoulou K, Masterson B, Poon L, Cleare AJ. Multidimensional tool to quantify treatment resistance in depression: the Maudsley Staging Method. Feb 177–184
Fekadu A, Wooderson SC, Markopoulou K, Cleare AJ. Maudsley Staging Method for treatment-resistant depression: prediction of longer-term outcome and persistence of symptoms. July 952–957
Feldman S see Kelly DL
Fellows I see Zisook S
Fernandes BS see de Lucena D
Feusner JD see Bystritsky A
Findling RL. Safety and tolerability of bipolar disorder treatment in youth. Nov e44
Findling RL. Treatment options for children and adolescents with bipolar disorder. Sept e34
Findling RL, Nyilas M, Forbes RA, McQuade RD, Jin N, Iwamoto T, Ivanova S, Carson WH, Chang K. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. Oct 1441–1451
Findling RL see Gao K; Kemp DE
Fink M see Rasmussen KG
Finucane B see Bourgeois JA
Fischer HD see Shulman KI
Fischer P see Mossaheb N
Fischetti C see Taylor DM
Fishbain DA. Evidence-based treatment paradigms for depressed patients with pain and physical symptoms. July e22
Fishbain DA. Remission as the "gold standard" of treatment for depression with and without physical symptoms. Apr e07
Fleischhacker WW. Tolerability of antipsychotics: recent controversies and future management. Mar e06
Fleischhacker WW see Kane JM; Leucht S; Tschoner A
Fletcher RJ, Havercamp SM, Ruedrich SL, Benson BA, Barnhill LJ, Cooper SA, Stavrakaki C. Clinical usefulness of the Diagnostic Manual-Intellectual Disability for mental disorders in persons with intellectual disability: results from a brief field survey. July 967–974
Flosnik DL, Cortese BM, Uhde TW. Cataplexy in anxious patients: is subclinical narcolepsy underrecognized in anxiety disorders? June 810–816
Fluitman SBAHA see Vulink NCC
Flynn HA see Muzik M
Fogel I see Vanderburg DG
Forbes RA see Findling RL
Ford JD, Connor DF, Hawke J. Complex trauma among psychiatrically impaired children: a cross-sectional, chart-review study. Aug 1155–1163
Ford JD, Elhai JD, Ruggiero KJ, Frueh BC. Refining posttraumatic stress disorder diagnosis: evaluation of symptom criteria with the National Survey of Adolescents. May 748–755
Fornari V see Soto EC
Fostick L see Zohar J
Francey SM see McGorry PD
Franco C see Sanchez-Moreno J
Frankenburg FR. Folate supplementation: is it safe and effective? [letter with reply] May 767
Frederickson AM see Soto EC
Freedman R. Learning to review [commentary]. Nov 1599–1600
Freeman MP. Breastfeeding and antidepressants: clinical dilemmas and expert perspectives [ASCP Corner]. Feb 291–292
Freeman MP. Commentaries on peer review and the evolving journal [introduction]. Nov 1598
Freeman MP. Complementary and alternative medicine (CAM): considerations for the treatment of major depressive disorder. Suppl 5, 4–6
Freeman MP. Early career psychiatry [introduction]. Nov 1571
Freeman MP. Hot topics and clinical implications [introduction]. Dec 1687
Freeman MP. Imperfect literature and evidence-based medicine [introduction]. Mar 412–413
Freeman MP. Location, location, location: the role of place in career development [introduction]. July 1024–1025
Freeman MP. Managing depression during pregnancy. July e25
Freeman MP. Omega-3 fatty acids in major depressive disorder. Suppl 5, 7–11
Freeman MP. Perinatal mental health: new data regarding risk factors and

treatment considerations [introduction]. Sept 1289
Freeman MP. Perinatal psychiatry: the challenges of making rational treatment decisions at the interface of psychiatry and obstetrics [introduction]. Sept 1311–1312
Freeman MP. Postpartum depression treatment and breastfeeding. Sept e35
Freeman MP. This month's ECP selections [introduction]. Jan 101–102
Freeman MP see Gelenberg AJ
Freeman SA. Benzodiazepine stigma persists [letter]. Dec 1727–1729
Freeman SA. Suicide risk and psychopharmacology: assessment and management of acute and chronic risk factors [ASCP Corner]. July 1052–1053
Freudenreich O, Henderson DC, Macklin EA, Evins AE, Fan X, Cather C, Walsh JP, Goff DC. Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial. Dec 1674–1680
Fried R see Henin A
Friedman ES. Medical monitoring in patients with bipolar disorder: clinical recommendations. Aug e27
Friedman M see Menzin J
Frölich L see Hampel H
Frueh BC see Ford JD
Frye MA see Altshuler LL; Benazzi F; Goldberg JF
Fu K-w, Yip PSF. Estimating the risk for suicide following the suicide deaths of 3 Asian entertainment celebrities: a meta-analytic approach. June 869–878
Fugon L see Roux P
Fu-I L, Boarati MA, Stravogiannis A, Wang Y-P. Use of risperidone long-acting injection to support treatment adherence and mood stabilization in pediatric bipolar patients: a case series [letter]. Apr 604–606
Furukori H see Yasui-Furukori N
Fusar-Poli P, Howes OD, McGuire P. Pseudohallucinations versus true hallucinations in prodromal psychosis: does it really matter? [letter] July 1056–1057
Gádoros J see Baji I
Gahm GA see Reger MA
Galea S see Abrams RC
Gallagher GL see Lee P
Gallop R see Jaffee WB
Gama CS see de Lucena D
Gambassi G see Liperoti R
Gamel NN see Koran LM
Gandelman K, Alderman JA, Glue P, Lombardo I, LaBadie RR, Versavel M, Preskorn SH. Impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial. Jan 58–62
Gane LW see Bourgeois JA
Ganocy SJ see Gao K; Kemp DE
Ganoczy D see Ilgen MA
Gao K, Tolliver BK, Kemp DE, Ganocy SJ, Bilali S, Brady KL, Findling RL, Calabrese JR. Correlates of historical suicide attempt in rapid-cycling bipolar disorder: a cross-sectional assessment. July 1032–1040
Gao K see Kemp DE
Garnet B see Barry DT
Garriock HA, Hamilton SP. Genetic studies of drug response and side effects in the STAR*D study, part 1 [ASCP Corner]. Aug 1186–1187
Garriock HA, Hamilton SP. Genetic studies of drug response and side effects in the STAR*D study, part 2 [ASCP Corner]. Sept 1323–1325
Gärtner J see Schneider A
Gasser T see Hampel H
Gaudiano BA, Uebelacker LA, Epstein-Lubow G, Miller IW. Premature conclusions about psychotherapy for dysthymia [letter with reply]. Aug 1188–1189
Gaynes BN. Identifying difficult-to-treat depression: differential diagnosis, subtypes, and comorbidities. Suppl 6, 10–15
Gee D see Gleeson JFM
Gelenberg AJ. e-Etiquette [editorial]. Jan 103
Gelenberg AJ. Peer review perspective for early career psychiatrists [commentary]. Nov 1599
Gelenberg AJ, Freeman MP. JCP's Circle of Honor and peer reviewers [editorial]. Jan 6–10
Gentil V. Bipolar disorder and concurrent psychiatric and medical disorders. Aug e29
Gentile S, Bellantuono C. Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of fetal major malformations: focus on paroxetine. Mar 414–422
Gentzler AL see Liu X
George CJ see Baji I; Liu X
Gersons BPR see Smid GE
Ghaemi SN. Reliability, not overdiagnosis [letter with reply]. Apr 603
Ghaemi SN see Goldberg JF
Gibertini M see Rickels K
Giglio LF see de Lucena D
Gignac M see Wilens TE
Gill MK see Romero S
Giltay EJ see Wiersma JE
Gleeson JFM, Cotton SM, Alvarez-Jimenez M, Wade D, Gee D, Crisp K, Pearce T, Newman B, Spiliotacopoulos D, Castle D, McGorry PD. Randomized controlled trial of relapse prevention therapy for first-episode psychosis patients. Apr 477–486
Glick ID see Janicak PG
Glitz DA see Moore GJ
Glover BA see Newport DJ
Glue P see Gandelman K
Gluud C see Krogh J
Goff DC see Freudenreich O; Kane JM
Goikolea JM see Sanchez-Moreno J; Scott J
Gold JM see Kelly DL
Goldberg JF. Reply to de Leon J: How should research productivity be assessed in early career psychiatric researchers? research funding versus scientific productivity [letter]. Sept 1327–1329
Goldberg JF. Role of divalproex plus olanzapine in outpatient mixed-episode bipolar I disorder [commentary]. Nov 1548–1550
Goldberg JF, Brooks JO III, Kurita K, Hoblyn JC, Ghaemi SN, Perlis RH, Miklowitz DJ, Ketter TA, Sachs GS, Thase ME. Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD. Feb 155–162
Goldberg JF, Calabrese JR, Saville BR, Frye MA, Ketter TA, Suppes T, Post RM, Goodwin FK. Mood stabilization and destabilization during acute and continuation phase treatment for bipolar I disorder with lamotrigine or placebo. Sept 1273–1280
Goldberg RW see Dickerson FB
Goldenberg DL. Using multidisciplinary care to treat fibromyalgia. May e13
Goldfinger SM see Weiden PJ
Goldstein BI, Kemp DE, Soczynska JK, McIntyre RS. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. Aug 1078–1090
Goldstein BI see Romero S
Goldstein MZ, Cummings MR. Review of Narrow WE, First MB, Sirovatka PJ, Regier DA (eds): *Age and Gender Considerations in Psychiatric Diagnosis: A Research Agenda for DSM-V.* May 772–773
Goldstein RB, Grant BF. Three-year follow-up of syndromal antisocial behavior in adults: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions. Sept 1237–1249
Goldstein TR see Romero S
Golshan S see Zisook S
Gomes FA see de Lucena D
Gómez-Beneyto M see Tabarés-Seisdedos R

Gonzalez JM see Evans-Lacko SE
Gonzalez R see Dennehy EB
Gónzalez-Pinto A see Martinez-Aran A; Sanchez-Moreno J; Tabarés-Seisdedos R
Goodman DW see Adler LA
Goodwin FK see Goldberg JF
Goodwin GM, Emsley R, Rembry S, Rouillon F, Agomelatine Study Group. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. Aug 1128–1137
Goodwin GM see Martinez-Aran A
Goracci A see Fagiolini A
Gorwood PAPM see Corruble E
Goswami R see Moeller KE
Graff F see Jaffee WB
Grann M see Fazel S
Grant BF see Goldstein RB
Grant JE, Desai RA, Potenza MN. Relationship of nicotine dependence, subsyndromal and pathological gambling, and other psychiatric disorders: data from the National Epidemiologic Survey on Alcohol and Related Conditions. Mar 334–343
Greco C see Bourgeois JA
Greden JF. Treating depression and pain. June e16
Green AI see Nasrallah HA
Greist JH see Laska EM
Grey PM. Can *some* patients successfully discontinue SSRIs? [letter with reply] Oct 1477–1478
Griffin ML see Jaffee WB
Grigsby J see Bourgeois JA
Grohmann R see Lange-Asschenfeldt C
Gross AF, Wiechers IR, Stern TA. Peer review by early career psychiatrists: an opportunity for development [commentary]. Nov 1600–1601
Grosz DE see Oskooilar N
Grunze H see Altshuler LL
Guarino J see Nakamura M
Guggenheim FG. Review of Sanguineti VR: *The Rosetta Stone of the Human Mind: Three Languages to Integrate Neurobiology and Psychology.* Feb 300–301
Guico-Pabia CJ see Soares CN
Guidi J see Weiss AP
Gur RE see Nasrallah HA
Gutheil TG. Review of Simon RI, Tardiff K (eds): *Textbook of Violence Assessment and Management.* Oct 1482–1483
Gutierrez F see Castellvi P
Gutiérrez M see Sánchez P
Hagerman PJ see Bourgeois JA
Hagerman RJ see Bourgeois JA
Hägg S see Karlsson J
Haile C see Chen JX
Halldorson TI see Strøm M
Haltzman SD. Review of Allen JG, Fonagy P, Bateman AW: *Mentalizing in Clinical Practice.* Aug 1196
Hamdani M see Adler LA
Hamer AM Hartung DM
Hamilton SP see Garriock HA
Hampel H, Ewers M, Bürger K, Annas P, Mörtberg A, Bogstedt A, Frölich L, Schröder J, Schönknecht P, Riepe MW, Kraft I, Gasser T, Leyhe T, Möller H-J, Kurz A, Basun H. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. June 922–931
Hansen L see Kane JM
Hanusa BH see Bodnar LM; Lanza di Scalea T
Harlow MC. Review of Boots DP: *Mental Health and Violent Youth: A Developmental/Lifecourse Perspective.* June 940–941
Haro J-M see Tabarés-Seisdedos R
Hartman CA see 't Hart-Kerkhoffs LA
Hartong EGThM see van der Loos MLM
Hartung DM, Wisdom JP, Pollack DA, Hamer AM, Haxby DG, Middleton L, McFarland BH. Reply to Stensland MD: Overestimating the prevalence of subtherapeutic dosing of atypical antipsychotics [letter]. Aug 1189–1191
Harvey PD see Wingo AP
Hasan A see Schneider A
Haukka J see Suominen K
Havercamp SM see Fletcher RJ
Hawke J see Ford JD
Haxby DG Hartung DM
Hayashida K see Matsunaga H
Hébert C see Chenu F
Hellemann G see Altshuler LL
Henderson DC see Freudenreich O
Hendriks EH see Schiffer AA
Henin A, Mick E, Biederman J, Fried R, Hirshfeld-Becker DR, Micco JA, Miller KG, Rycyna CC, Wozniak J. Is psychopharmacologic treatment associated with neuropsychological deficits in bipolar youth? Aug 1178–1185
Henley DB see Trivedi MH
Hennings A, Zill P, Rief W. Serotonin transporter gene promoter polymorphism and somatoform symptoms. Nov 1536–1539
Henry C see Martinez-Aran A
Hentz JG see Stonnington CM
Herrmann N see Rapoport MJ; Shulman KI
Hessl D see Bourgeois JA
Hickie I see McGorry PD
Hinterhuber H see Deisenhammer EA
Hirschel S see Schneider A
Hirshfeld-Becker DR see Henin A
Hoblyn JC see Goldberg JF
Hofman A see van den Berg JF
Hoge EA see Simon NM
Hoggatt KJ see Ilgen MA
Hollon SD see Cuijpers P
Hong JP see Lee P
Horesh D see Solomon Z
Horne RL see Keck PE Jr
Horst RO. Review of Martin A, Volkmar FR (eds): *Lewis's Child and Adolescent Psychiatry: A Comprehensive Textbook, 4th ed.* Feb 299
Houston JP, Tohen M, Degenhardt EK, Jamal HH, Liu LLL, Ketter TA. Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study. Nov 1540–1547
Hovens JGFM see Wiersma JE
Howard MO see Perron BE
Howes OD see Fusar-Poli P
Hu Q see Smith RC
Hunt J see Romero S
Huo CY see Shulman KI
Huremovic D see Rao NR
Husain MM, Rush AJ, Wisniewski SR, McClintock SM, Fava M, Nierenberg AA, Davis L, Balasubramani GK, Young E, Albala AA, Trivedi MH. Family history of depression and therapeutic outcome: findings from STAR*D. Feb 185–195
Husain MM see Rasmussen KG
Hynan LS see Siddique H
Ilgen MA, Downing K, Zivin K, Hoggatt KJ, Kim HM, Ganoczy D, Austin KL, McCarthy JF, Patel JM, Valenstein M. Exploratory data mining analysis identifying subgroups of patients with depression who are at high risk for suicide. Nov 1495–1500
Ing C-M see Deisenhammer EA
Inrig SJ see Brandon AR
Iosif A-M see Romero S
Israeli Consortium on PTSD see Zohar J
Ivanova S see Findling RL
Iwamoto T see Findling RL
Iyengar M see Rapaport MH
Iyengar S see Romero S
Jacob MK, Ash P. Venlafaxine-induced complex visual hallucinations in a 17-year-old boy [letter]. Apr 601–603
Jaffe A see Citrome L
Jaffee WB, Griffin ML, Gallop R, Meade CS, Graff F, Bender RE, Weiss RD. Depression precipitated by alcohol use in patients with

co-occurring bipolar and substance use disorders. Feb 171–176
Jain R. Epidemiology and recognition of pain and physical symptoms in depression. Mar e04
Jain R. Implications of pain and physical symptoms in depression. June e19
Jain R. Pain and the brain: lower back pain. Feb e41
Jain R. Treating patients with emotional and physical symptoms. May e15
Jain R, Culpepper L, Maletic V. Pain and the brain 2: the recognition and management of chronic pain in primary care. Nov e43
Jamal HH see Houston JP
Janicak PG, Glick ID, Marder SR, Crandall DT, McQuade RD, Marcus RN, Eudicone JM, Assunção-Talbott S. Acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies. Jan 25–35
Jansen LM see 't Hart-Kerkhoffs LA
Jansen WT see Szegedi A
Jaussent I see Ritchie K
Jerrell JM see McIntyre RS
Jeste DV see Zisook S
Jiang Q see Soares CN
Jiménez D see Castellvi P
Jin N see Findling RL
Johannes CB, Clayton AH, Odom DM, Rosen RC, Russo PA, Shifren JL, Monz BU. Distressing sexual problems in United States women revisited: prevalence after accounting for depression. Dec 1698–1706
Joost van Wattum P. Review of Bezchlibnyk-Butler KZ, Virani AS (eds): *Clinical Handbook of Psychotropic Drugs for Children and Adolescents, 2nd rev ed.* Feb 301
Joseph DI. Review of Merlino JP, Jacobs MS, Kaplan JA, Moritz KL (eds): Freud *at 150: 21st-Century Essays on a Man of Genius.* Aug 1194
Joshi D see Barry DT
Jungwirth S see Mossaheb N
Kahn MW. Three (ancient) questions for the academic psychiatrist [commentary]. July 1051
Kalali AH see Laska EM
Kane JM. Creating a health care team to manage chronic medical illnesses in patients with severe mental illness: the public policy perspective. Suppl 3, 37–42
Kane JM, Correll CU, Goff DC, Kirkpatrick B, Marder SR, Vester-Blokland E, Sun W, Carson WH, Pikalov A, Assunção-Talbott S. Multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. Oct 1348–1357
Kane JM, Fleischhacker WW, Hansen L, Perlis R, Pikalov A III, Assunção-Talbott S. Akathisia: an updated review focusing on second-generation antipsychotics. May 627–643
Kane JM, Osuntokun O, Kryzhanovskaya LA, Xu W, Stauffer VL, Watson SB, Breier A. 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. Apr 572–581
Kane JM see Nasrallah HA
Kane ME see Manning JS
Kaneko S see Yasui-Furukori N
Kang JI, Kim C-H, Namkoong K, Lee C-i, Kim SJ. Randomized controlled study of sequentially applied repetitive transcranial magnetic stimulation in obsessive-compulsive disorder. Dec 1645–1651
Kaplan Z see Zohar J
Kapornai K see Baji I
Kapur S see Uchida H
Karlsson J, Wallerstedt SM, Star K, Bate A, Hägg S. Sudden cardiac death in users of second-generation antipsychotics [letter]. Dec 1725–1726
Kasckow JW see Zisook S
Kaser S see Tschoner A
Kashima H Nakajima S
Katz CL. Review of Blumenfield M, Ursano RJ (eds): *Intervention and Resilience After Mass Trauma.* Nov 1611
Kaushik S, Maccabee N, Kaushik S, Lindenmayer J-P. Activation induced by high-dose ziprasidone: a case report [letter]. Sept 1326–1327
Kaushik S see Kaushik S; Lindenmayer J-P
Kaushik S see Lindenmayer J-P
Kavoussi RJ see Coccaro EF
Kay SJ see Klass ET
Kearney TE see Ciranni MA
Keck PE Jr, Versiani M, Warrington L, Loebel AD, Horne RL. Long-term safety and efficacy of ziprasidone in subpopulations of patients with bipolar mania. June 844–851
Keck PE see Altshuler LL
Keith S see Shajahan P
Keller M see Romero S
Kellner CH see Rasmussen KG
Kelly DI see Dennehy EB
Kelly DL, Buchanan RW, Boggs DL, McMahon RP, Dickinson D, Nelson M, Gold JM, Ball MP, Feldman S, Liu F, Conley RR. Randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia. Apr 518–525
Kelly E see Smith RC
Kemmler G see Deisenhammer EA
Kemp DE, Gao K, Ganocy SJ, Elhaj O, Bilali SR, Conroy C, Findling RL, Calabrese JR. Six-month, double-blind, maintenance trial of lithium monotherapy versus the combination of lithium and divalproex for rapid-cycling bipolar disorder and co-occurring substance abuse or dependence. Jan 113–121
Kemp DE see Gao K; Goldstein BI
Kenealy DC see Surman CBH
Kennard BD see Vitiello B
Kennedy SH see Levitan RD; Ravindran AV
Kerle IA see Dehning S
Kerwin LE see Bystritsky A
Keshavan MS see McGorry PD; Nasrallah HA
Ketter TA. Treating bipolar disorder: monotherapy versus combination therapy. Feb e42
Ketter TA see Goldberg JF; Houston JP
Ketzer CR see Tramontina S
Khalsa H-MK see Salvatore P
Khan A see Lindenmayer J-P; Smith RC
Khantzian EJ, Albanese MJ. Self-medication, bipolar disorders, and stimulant dependence [letter with reply]. June 935–936
Kilbourne AM see Perron BE
Kim B-N, Kim J-W, Kim H-W, Shin M-S, Cho S-C, Choi NH, Ahn H, Lee S-Y, Ryu J, Yun M-J. 6-month follow-up study of posttraumatic stress and anxiety/depressive symptoms in Korean children after direct or indirect exposure to a single incident of trauma. Aug 1148–1154
Kim C-H see Kang JI
Kim E see Meyer JM
Kim HM see Ilgen MA
Kim H-W see Kim B-N
Kim J-W see Kim B-N
Kim SJ see Kang JI
Kingdon D see Malik N
Kinon BJ see Lindenmayer J-P
Kiriike N see Matsunaga H
Kirkpatrick B see Kane JM
Kiss E see Baji I
Kivlahan DR see Shores MM
Klass ET, Milrod BL, Leon AC, Kay SJ, Schwalberg M, Li C, Markowitz JC. Does interpersonal loss preceding panic disorder onset moderate response to psychotherapy? an exploratory study. Mar 406–411
Kleber RJ see Smid GE
Klein DN see Kocsis JH
Klein E see Zohar J

Kleinman NL, Brook RA, Doan JF, Melkonian AK, Baran RW. Health benefit costs and absenteeism due to insomnia from the employer's perspective: a retrospective, case-control, database study. Aug 1098–1104
Klosterkötter J see McGorry PD
Knapp RG see Rasmussen KG
Knight BT see Newport DJ
Kocsis JH, Leon AC, Markowitz JC, Manber R, Arnow B, Klein DN, Thase ME. Patient preference as a moderator of outcome for chronic forms of major depressive disorder treated with nefazodone, cognitive behavioral analysis system of psychotherapy, or their combination. Mar 354–361
Koeter MWJ see Bockting CLH; ten Doesschate MC
Kohlhase J see Schneider A
Kopelowicz A. Review of Leong FTL, Leach MM (eds): *Suicide Among Racial and Ethnic Minority Groups: Theory, Research, and Practice*. Sept 1331
Koran LM, Aboujaoude E, Gamel NN. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder. Nov 1530–1535
Kormilachev M see Schwartz M
Kornstein SG see Soares CN
Kosten TR see Chen JX
Kovacs M see Baji I; Liu X
Kozin DS see Simeon D
Kraft I see Hampel H
Krakowski M see Citrome L
Kratochvil CJ see Vitiello B
Kremer CME see Vanderburg DG
Kreyenbuhl J see Dickerson FB
Krogh J, Saltin B, Gluud C, Nordentoft M. The DEMO Trial: a randomized, parallel-group, observer-blinded clinical trial of strength versus aerobic versus relaxation training for patients with mild to moderate depression. June 790–800
Kruesi MJP see Wilens TE
Krupitzki H see Taragano FE
Krystal JH. Evolution of the psychiatry research journal [commentary]. Nov 1601–1602
Kryzhanovskaya LA, Robertson-Plouch CK, Xu W, Carlson JL, Merida KM, Dittmann RW. Safety of olanzapine in adolescents with schizophrenia or bipolar I disorder: a pooled analysis of 4 clinical trials. Feb 247–258. Correction, Dec 1729
Kryzhanovskaya LA see Kane JM
Kulkarni PM see Lindenmayer J-P
Kunz M see de Lucena D
Kupka RW see Altshuler LL
Kurita K see Goldberg JF
Kurz A see Hampel H
Kushnir M see Schwartz M
LaBadie RR see Gandelman K
Ladstaetter E see Chenu F
LamLit Study Group see van der Loos MLM
Lanctôt KL see Rapoport MJ
Landi F see Liperoti R
Lange-Asschenfeldt B see Lange-Asschenfeldt C
Lange-Asschenfeldt C, Grohmann R, Lange-Asschenfeldt B, Engel RR, Rüther E, Cordes J. Cutaneous adverse reactions to psychotropic drugs: data from a multicenter surveillance program. Sept 1258–1265
Långström N see Fazel S
Lanza di Scalea T, Hanusa BH, Wisner KL. Sexual function in postpartum women treated for depression: results from a randomized trial of nortriptyline versus sertraline. Mar 423–428
Lapane KL see Liperoti R
Larsen LM see Moeller KE
Laska EM, Mallinckrodt CH, Mundt JC, Leber P, Vaccarino AL, Kalali AH, Greist JH. Assessing onset of treatment benefit in depression and anxiety: conceptual considerations. Aug 1138–1145
Laursen TM, Agerbo E, Pedersen CB. Bipolar disorder, schizoaffective disorder, and schizophrenia overlap: a new comorbidity index. Oct 1432–1438
Lavedan C see Volpi S
Lawson AH see Stensland MD
Lazarus A see Cutler AJ
Le A see Soto EC
LeBeau RT see Simon NM
Leber P see Laska EM
Leboyer M see Martinez-Aran A
Lee B see Lee P
Lee C-i see Kang JI
Lee E, Leung C-M. High-risk groups for charcoal-burning suicide attempt in Hong Kong, China, 2004 [letter]. Mar 431
Lee H-C see Lin H-C
Lee M-B see Chen Y-Y
Lee MS see Lee P
Lee P, Zhang M, Hong JP, Chua H-C, Chen K-P, Tang SW, Chan BTM, Lee MS, Lee B, Gallagher GL, Dossenbach M. Frequency of painful physical symptoms with major depressive disorder in Asia: relationship with disease severity and quality of life. Jan 83–91
Lee RJ see Coccaro EF
Lee SJC see Brandon AR
Lee S-Y see Kim B-N
Lee TMC, Chan S-C, Raine A. Hyperresponsivity to threat stimuli in domestic violence offenders: a functional magnetic resonance imaging study. Jan 36–45
Lehman D see Zisook S
Lenze EJ see Sheffrin M
Leon AC see Abrams RC; Klass ET; Kocsis JH
Leong RW see Newcomer JW
Leonova-Edlund J see Newcomer JW
Lerch B see Simeon D
Leslie DL see Mohamed S
Letierce A see Corruble E
Leucht S, Fleischhacker WW. Reply to Tabarés-Seisdedos R: Importance of negative comorbidity [letter]. Aug 1191–1192
Leung C-M see Lee E
Leung EM see Levitan RD
Leverich GS see Altshuler LL
Levine J see Citrome L
Levine M see Surman CBH
Levitan RD, Atkinson L, Pedersen R, Buis T, Kennedy SH, Chopra K, Leung EM, Segal ZV. Novel examination of atypical major depressive disorder based on attachment theory. June 879–887
Levitan RD, Atkinson L, Pedersen R, Buis T, Kennedy SH, Chopra K, Leung EM, Segal ZV. Reply to Markowitz JC: Does depressive state influence reported attachment status? [letter] Dec 1726–1727
Lewis-Fernández R see Markowitz JC
Leyhe T see Hampel H
Li C see Abrams RC; Klass ET
Li EJ see Shores MM
Li X see Shen J
Liao S-C see Chen Y-Y
Libby AM see Valuck RJ
Licamele L see Volpi S
Lichtenstein P see Fazel S
Liebowitz MR, Asnis G, Mangano R, Tzanis E. Double-blind, placebo-controlled, parallel-group, flexible-dose study of venlafaxine extended release capsules in adult outpatients with panic disorder. Apr 550–561
Liew A see Verma SK
Lin H-C, Chen Y-H, Lee H-C. Prenatal care and adverse pregnancy outcomes among women with schizophrenia: a nationwide population-based study in Taiwan. Sept 1297–1303
Lindenmayer J-P, Khan A, Wance D, Maccabee N, Kaushik S, Kaushik S. Outcome evaluation of a structured educational wellness program in patients with severe mental illness. Oct 1385–1396

Lindenmayer J-P, Liu-Seifert H, Kulkarni PM, Kinon BJ, Stauffer V, Edwards SE, Chen L, Adams DH, Ascher-Svanum H, Buckley PF, Citrome L, Volavka J. Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. July 990–996
Lindenmayer J-P see Cho DY; Kaushik S; Saavedra-Velez C; Smith RC
Liperoti R, Onder G, Landi F, Lapane KL, Mor V, Bernabei R, Gambassi G. All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: a retrospective cohort study. Oct 1340–1347
Lipschitz A see Rapaport MH
Liu F see Kelly DL
Liu LLL see Houston JP
Liu X, Gentzler AL, George CJ, Kovacs M. Responses to depressed mood and suicide attempt in young adults with a history of childhood-onset mood disorder. May 644–652
Liu YH see Chen JX
Liu-Seifert H see Lindenmayer J-P
Lobato MI see de Lucena D
Loebel A see Nakamura M
Loebel AD see Keck PE Jr
Lomax JW, Bejjani C. Review of Barnhill JW (ed): *Approach to the Psychiatric Patient: Case-Based Essays by the Faculties of Weill Cornell Medical College and Columbia University College of Physicians and Surgeons.* Dec 1730
Lombardo I see Gandelman K
Loñ L see Taragano FE
Lönnqvist J see Suominen K
Looper KJ see Desmarais JE.
Lopez-Castroman J see Blasco-Fontecilla H
Lopez-Duran NL see Baji I
Luckenbaugh D see Machado-Vieira R
Luijendijk HJ see van den Berg JF
Luteijn ML see van der Loos MLM
Lydiard RB see Rapaport MH
Lyketsos CG see Taragano FE
Lynn DJ. Review of Goodwin FK, Jamison KR (eds): *Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression, 2nd ed.* Mar 435
Maccabee N see Kaushik S; Lindenmayer J-P
Machado-Vieira R, Yuan P, Brutsche N, DiazGranados N, Luckenbaugh D, Manji HK, Zarate CA Jr. Brain-derived neurotrophic factor and initial antidepressant response to an *N*-methyl-D-aspartate antagonist. Dec 1662–1666
Macklin EA see Freudenreich O
MacRae A see Shajahan P
Madaan V. Review of Findling RL (ed): *Clinical Manual of Child and Adolescent Psychopharmacology.* Sept 1331–1332
Maggini C see Salvatore P
Maina G see Perahia DGS
Majjiga C see Shajahan P
Malafosse A see Ritchie K
Maletic V see Jain R
Malhi GS see Anand S
Malhotra AK see Volpi S
Malik N, Kingdon D, Pelton J, Mehta R, Turkington D. Effectiveness of brief cognitive-behavioral therapy for schizophrenia delivered by mental health nurses: relapse and recovery at 24 months. Feb 201–207
Mallinckrodt CH see Laska EM
Malloy-Diniz LF see Neves FS
Mamo DC see Uchida H
Manber R see Kocsis JH
Mangano R see Liebowitz MR
Manji HK see Machado-Vieira R; Moore GJ
Manning JS, Kane ME. Overdiagnosis and underdiagnosis of bipolar disorder [letter with reply]. Jan 143–144
Marcellin F see Roux P
March JS see Vitiello B
Marcus RN see Janicak PG
Marcus SM see Muzik M
Marder SR. Review of Freeman C, Tyrer P (eds): *Research Methods in Psychiatry, 3rd ed.* Jan 145
Marder SR see Janicak PG; Kane JM
Markopoulou K see Fekadu A
Markowitz JC, Meehan KB. Does depressive state influence reported attachment status? [letter with reply] Dec 1725
Markowitz JC, Patel SR, Balan IC, Bell MA, Blanco C, Brave Heart MYH, Buttacavoli Sosa S, Lewis-Fernández R. Toward an adaptation of interpersonal psychotherapy for Hispanic patients with DSM-IV major depressive disorder. Feb 214–222
Markowitz JC see Klass ET; Kocsis JH
Markus EM, Miller LJ. Other side of the risk equation: exploring risks of untreated depression and anxiety in pregnancy [commentary]. Sept 1314–1315
Maron E, Eller T, Vasar V, Nutt DJ. Effects of bupropion augmentation in escitalopram-resistant patients with major depressive disorder: an open-label, naturalistic study [letter]. July 1054–1056
Márquez C see Castellvi P
Martelon M see Wilens TE
Martinez-Aran A, Scott J, Colom F, Torrent C, Tabarés-Seisdedos R, Daban C, Leboyer M, Henry C, Goodwin GM, González-Pinto A, Cruz N, Sánchez-Moreno J, Vieta E. Treatment nonadherence and neurocognitive impairment in bipolar disorder. July 1017–1023
Martinez-Aran A see Sanchez-Moreno J
Martínez-Garcia O see Crespo-Facorro B
Martín-Santos R see Castellvi P
Marzuk PM see Abrams RC
Masand PS see Pae C-U
Masterson B see Fekadu A
Mata I see Crespo-Facorro B
Matsumoto AM see Shores MM
Matsunaga H, Nagata T, Hayashida K, Ohya K, Kiriike N, Stein DJ. Long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder. June 863–868
Matz J see Dehning S
May DE see Vitiello B
Mayer L see Baji I
Mayes TL see Vitiello B
McCarthy JF see Ilgen MA
McClintock SM see Husain MM
McCue RE, Unuigbe FE, Charles RA, Orendain GCM, Waheed R. Treatment of morbidly obese psychotic patients with molindone: three case reports [letter]. Nov 1606–1607
McElroy SL. Obesity in patients with severe mental illness: overview and management. Suppl 3, 12–21
McElroy SL see Altshuler LL
McFarland BH Hartung DM
McGorry PD, Nelson B, Amminger GP, Bechdolf A, Francey SM, Berger G, Riecher-Rössler A, Klosterkötter J, Ruhrmann S, Schultze-Lutter F, Nordentoft M, Hickie I, McGuire P, Berk M, Chen EYH, Keshavan MS, Yung AR. Intervention in individuals at ultra-high risk for psychosis: a review and future directions. Sept 1206–1212
McGorry PD see Gleeson JFM
McGuire P see Fusar-Poli P; McGorry PD
McIntyre RS. Balancing the equation: managing comorbidities in patients with severe mental illness [introduction]. Suppl 3, 4
McIntyre RS. Managing weight gain in patients with severe mental illness. July e23
McIntyre RS. Overview of managing medical comorbidities in patients with severe mental illness. June e17
McIntyre RS. Understanding needs, interactions, treatment, and expectations among individuals affected by bipolar disorder or schizophrenia: the UNITE Global Survey. Suppl 3, 5–11
McIntyre RS, Jerrell JM. Polypharmacy in children and adolescents treated for

major depressive disorder: a claims database study. Feb 240–246
McIntyre RS see Goldstein BI
McMahon RP see Kelly DL
McQuade RD see Findling RL; Janicak PG
Meade CS see Jaffee WB
Medeiros DW see de Lucena D
Medoff D see Dickerson FB
Meehan KB see Markowitz JC
Mehta R see Malik N
Meinardi JCM see Vulink NCC
Melkonian AK see Kleinman NL
Menzin J, Sussman M, Tafesse E, Duczakowski C, Neumann P, Friedman M. Model of the economic impact of a bipolar disorder screening program in primary care. Sept 1230–1236
Merida KM see Kryzhanovskaya LA
Meulien D see Newcomer JW
Meyer JM, Rosenblatt LC, Kim E, Baker RA, Whitehead R. Moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia. Mar 318–325
Micco JA see Henin A
Michel L see Roux P
Mick E see Henin A; Surman CBH
Middleton L Hartung DM
Miklowitz DJ see Goldberg JF
Miller F see Newcomer JW
Miller HS see Davis MF
Miller IW see Gaudiano BA
Miller KG see Henin A
Miller LJ see Markus EM
Miller MD see Sheffrin M
Milrod BL see Klass ET
Minderaa RB see 't Hart-Kerkhoffs LA
Mischoulon D, Fava M, Stahl SM. Reply to Frankenburg FR: Folate supplementation: is it safe and effective? [letter] May 767–769
Mischoulon D, Papakostas GI, Dording CM, Farabaugh AH, Sonawalla SB, Agoston AM, Smith J, Beaumont EC, Dahan LE, Alpert JE, Nierenberg AA, Fava M. Double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder. Dec 1636–1644
Mischoulon D see Fava M
Mitchell JE. Review of Fairburn CG: *Cognitive Behavior Therapy and Eating Disorders.* Aug 1194–1195
Moeller KE, Goswami R, Larsen LM. Myxedema madness rapidly reversed with levothyroxine [letter]. Nov 1607–1608
Mohamed S, Leslie DL, Rosenheck RA. Use of antipsychotics in the treatment of major depressive disorder in the U.S. Department of Veterans Affairs. June 906–912
Mohamed S see Zisook S
Mohan T, Bastiampillai T, Dhillon R. Ziprasidone-induced angioedema: a case report [letter]. July 1054
Möller H-J see Hampel H
Moller HJ see Shen J
Montejo AL. Toward depression remission: balancing efficacy and tolerability. Oct e36
Montgomery SA see Cutler AJ
Monuteaux MC see Biederman J
Monz BU see Johannes CB
Moore GJ, Cortese BM, Glitz DA, Zajac-Benitez C, Quiroz JA, Uhde TW, Drevets WC, Manji HK. Longitudinal study of the effects of lithium treatment on prefrontal and subgenual prefrontal gray matter volume in treatment-responsive bipolar disorder patients. May 699–705
Mooren TTM see Smid GE
Mor V see Liperoti R
Mörtberg A see Hampel H
Mortensen EL see Strøm M
Moscardino U, Scrimin S, Capello F, Altoè G. Reply to van der Velden PG: Long-term effects of the terrorist attack in Beslan on adolescent survivors [letter]. June 934–935
Moses-Kolko E see Bodnar LM
Moshier SJ see Simon NM
Mosier KE see Schneider AL
Mossaheb N, Weissgram S, Zehetmayer S, Jungwirth S, Rainer M, Tragl K-H, Fischer P. Late-onset depression in elderly subjects from the Vienna Transdanube Aging (VITA) Study. Apr 500–508
Mueller M see Rasmussen KG
Mulcare L see Pundiak TM
Mulder PGH see van der Loos MLM
Müller N see Dehning S
Mulsant BH see Sheffrin M; Uchida H
Mundt JC see Laska EM
Murphy J see Shajahan P
Murray B see Rapoport MJ
Murru A, Castro P, Sanchez R, Benabarre A, Vieta E. Late-onset manic episode in a 91-year-old man without previous psychiatric history as a unique clinical manifestation of a pancreatic neoplasm [letter]. Feb 296–297
Muzik M, Marcus SM, Flynn HA. Psychotherapeutic treatment options for perinatal depression: emphasis on maternal-infant dyadic outcomes [commentary]. Sept 1318–1319
Nagata T see Matsunaga H
Nakagami T see Yasui-Furukori N
Nakajima S, Uchida H, Suzuki T, Watanabe K, Kashima H. Selective serotonin reuptake inhibitor–induced spermatorrhea in 2 patients [letter]. Aug 1192–1193
Nakamura M, Ogasa M, Guarino J, Phillips D, Severs J, Cucchiaro J, Loebel A. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. June 829–836
Namkoong K see Kang JI
Narvaez J see Tramontina S
Nasrallah HA. Review of Stahl SM: *Antipsychotics and Mood Stabilizers: Stahl's Essential Psychopharmacology, 3rd ed.* June 942
Nasrallah HA, Keshavan MS, Benes FM, Braff DL, Green AI, Gur RE, Kane JM, Perkins DO, Weiden PJ, Weinberger DR, Correll CU. Proceedings and Data From The Schizophrenia Summit: A Critical Appraisal to Improve the Management of Schizophrenia. Suppl 1, 4–46
Navinés R see Castellvi P
Nejtek VA, Avila M, Rush AJ. Reply to Khantzian EJ: Self-medication, bipolar disorders, and stimulant dependence [letter]. June 936–937
Nelson B see McGorry PD
Nelson JC. Augmentation and combination strategies in resistant depression. June e20
Nelson JC see Young JQ
Nelson L see Bourgeois JA
Nelson M see Kelly DL
Neumann P see Menzin J
Neven AK see van den Berg JF
Neves FS, Malloy-Diniz LF, Corrêa H. Suicidal behavior in bipolar disorder: what is the influence of psychiatric comorbidities? Jan 13–18
Newcomer JW. Comparing the safety and efficacy of atypical antipsychotics in psychiatric patients with comorbid medical illnesses. Suppl 3, 30–36
Newcomer JW, Ratner RE, Eriksson JW, Emsley R, Meulien D, Miller F, Leonova-Edlund J, Leong RW, Brecher M. 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone. Apr 487–499
Newcorn JH. Managing ADHD and comorbidities in adults. Feb e40
Newman B see Gleeson JFM
Newport DJ, Ritchie JC, Knight BT, Glover BA, Zach EB, Stowe ZN. Venlafaxine in human breast milk and

nursing infant plasma: determination of exposure. Sept 1304–1310
Niebler GE see Adler LA
Nienhuis JK see Perron BE
Nierenberg AA. Diagnosing and treating patients with symptoms of depression. Mar e05
Nierenberg AA. What have we learned about bipolar disorder from STEP-BD and other practical trials? Aug e30
Nierenberg AA see Husain MM; Mischoulon D
Nolan PE Jr see Davis MF
Nolen WA see Altshuler LL; van der Loos MLM
Nordentoft M see Krogh J; McGorry PD
Notten PJH see van der Loos MLM
Nutt DJ see Maron E
Nyilas M see Findling RL
Obadia Y see Roux P
Odom DM see Johannes CB
Ogasa M see Nakamura M
O'Hara MW see Dimidjian S
Ohya K see Matsunaga H
Ojeda N see Sánchez P
Olsen SF see Strøm M
Olson KR see Ciranni MA
Olvera RL see Evans-Lacko SE
Onder G see Liperoti R
Oquendo MA see Blasco-Fontecilla H
Orendain GCM see McCue RE
Orton HD see Valuck RJ
Oskooilar N, Wilcox CS, Tong M-L, Grosz DE. Body mass index and response to antidepressants in depressed research subjects [letter]. Nov 1609–1610
Oslin DW see Sayers SL
Østerdal ML see Strøm M
Osuntokun O see Kane JM; Trivedi MH
Ott HW see Tschoner A
Otto MW see Simon NM
Pae C-U, Patkar AA, Masand PS. Augmentation of dopaminergic agents for major depressive disorder [letter with reply]. Mar 432–433
Papakostas GI. Diagnostic assessment of major depressive disorder. Apr e09
Papakostas GI. Evidence for S-adenosyl-L-methionine (SAM-e) for the treatment of major depressive disorder. Suppl 5, 18–22
Papakostas GI. Initial treatment approaches for patients with major depressive disorder. June e18
Papakostas GI. Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. Suppl 6, 16–25
Papakostas GI see Mischoulon D
Parcell T see Biederman J; Wilens TE
Patel JM see Ilgen MA
Patel SR see Markowitz JC
Patkar AA see Pae C-U
Patsch JR see Tschoner A
Pearce T see Gleeson JFM
Pedersen CB see Laursen TM
Pedersen R see Levitan RD
Pedersen SS see Schiffer AA
Pedrini M see de Lucena D
Peele R, Cartwright S. Review of Minuchin P, Colapinto J, Minuchin S: *Working With Families of the Poor, 2nd ed.* Jan 146
Pelle AJ see Schiffer AA
Pelton J see Malik N
Peña J see Sánchez P
Penninx BWJH see Wiersma JE
Perahia DGS, Maina G, Thase ME, Spann ME, Wang F, Walker DJ, Detke MJ. Duloxetine in the prevention of depressive recurrences: a randomized, double-blind, placebo-controlled trial. May 706–716. Correction, Dec 1729
Pérez-Iglesias R see Crespo-Facorro B
Perez-Rodriguez MM see Blasco-Fontecilla H
Perkins DO see Nasrallah HA
Perlis RH. Efficacy of agents in treating mania. Apr e08
Perlis RH see Goldberg JF; Kane JM
Perron BE, Howard MO, Nienhuis JK, Bauer MS, Woodward AT, Kilbourne AM. Prevalence and burden of general medical conditions among adults with bipolar I disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Oct 1407–1415
Peselow ED see Pundiak TM
Petrides G see Rasmussen KG
Petti TA. Review of Kazdin AE, Rotella C: *The Kazdin Method for Parenting the Defiant Child: With No Pill, No Therapy, No Contest of Wills.* Jan 145–146
Petty C see Surman CBH
Petty CR see Biederman J
Pheula GF see Tramontina S
Philip NS, Carpenter LL, Tyrka AR, Whiteley LB, Price LH. Varenicline augmentation in depressed smokers: an 8-week, open-label study. July 1026–1031
Phillips D see Nakamura M
Pies RW. Pseudoresistant bipolar depression [letter with reply]. Oct 1476–1477
Pikalov A III see Kane JM
Pitts CD see Rapaport MH
Podawiltz A. Practical strategies for diagnosing and treating depression in women at midlife and beyond: chronic depression. Jan e03
Polcari A see Teicher MH
Pollack DA see Hartung DM
Pollack MH. Refractory generalized anxiety disorder. Suppl 2, 32–38
Pollack MH see Simon NM
Pollock BG see Sheffrin M; Uchida H
Poon L see Fekadu A
Poon LY see Verma SK
Popova E see Scott J
Porsteinsson AP, Cosman KM. Grumpy old men (and women): mere hassle or meaningful clinical evidence? [commentary] Apr 582–583
Posner K see Vitiello B
Post RM see Altshuler LL; Goldberg JF
Potenza MN see Desai RA; Grant JE
Potkin SG see Volpi S
Preskorn SH see Gandelman K
Pretorius HW see Bauer M
Price LH see Philip NS
Pundiak TM, Case BG, Peselow ED, Mulcare L. Reply to Grey PM: Can *some* patients successfully discontinue SSRIs? [letter] Oct 1477–1478
Quiroz JA see Moore GJ
Raine A see Lee TMC
Rainer M see Mossaheb N
Rao NR, Huremovic D. Review of Tasman A, Kay J, Lieberman JA, First MB, Maj M (eds): *Psychiatry, vols 1 & 2, 3rd ed.* Dec 1730–1731
Ramirez-Bonilla M see Crespo-Facorro B
Rapaport MH. Beyond acute treatment of depressive disorders. July e21
Rapaport MH. Helping patients with depression achieve wellness. May e11
Rapaport MH, Lydiard RB, Pitts CD, Schaefer D, Bartolic EI, Iyengar M, Carfagno M, Lipschitz A. Low doses of controlled-release paroxetine in the treatment of late-life depression: a randomized, placebo-controlled trial. Jan 46–57
Rapoport MJ, Lanctôt KL, Streiner DL, Bédard M, Vingilis E, Murray B, Schaffer A, Shulman KI, Herrmann N. Benzodiazepine use and driving: a meta-analysis. May 663–673
Rasmussen KG, Black JL III. Serotonin transporter gene status and electroconvulsive therapy outcomes: a retrospective analysis of 83 patients. Jan 92–94
Rasmussen KG, Mueller M, Rummans TA, Husain MM, Petrides G, Knapp RG, Fink M, Sampson SM, Bailine SH, Kellner CH. Is baseline medication resistance associated with potential for relapse after successful remission of a depressive episode with ECT? data from the Consortium for Research on Electroconvulsive Therapy (CORE). Feb 232–237
Ratner RE see Newcomer JW
Ravindran AV, Kennedy SH, Binder CE. Reply to Pae C-U: Augmentation of

dopaminergic agents for major depressive disorder [letter]. Mar 433–434
Reed CR see Rickels K
Regan WM. Review of Hardcastle M, Kennard D, Grandison S, Fagin L (eds): *Experiences of Mental Health In-patient Care: Narratives From Service Users, Carers and Professionals.* Mar 436–437
Reger MA, Gahm GA, Swanson RD, Duma SJ. Association between number of deployments to Iraq and mental health screening outcomes in US Army soldiers. Sept 1266–1272
Reiman EM. Untangling the roles of antidepressants and mood stabilizers in the treatment of Alzheimer's disease [introduction]. June 913–914
Reiman EM see Stonnington CM
Reinecke MA see Vitiello B
Rembry S see Goodwin GM
Remington G see Sockalingam S
Rettenbacher MA see Tschoner A
Reynolds CF III see Sheffrin M
Richardson GS, Zammit G, Wang-Weigand S, Zhang J. Safety and subjective sleep effects of ramelteon administration in adults and older adults with chronic primary insomnia: a 1-year, open-label study. Apr 467–476
Rickels K, Athanasiou M, Robinson DS, Gibertini M, Whalen H, Reed CR. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double blind, placebo-controlled trial. Mar 326–333
Rico-Villademoros F see Díaz-Marsá M
Riecher-Rössler A see McGorry PD
Riedel M see Dehning S
Rief W see Hennings A
Riepe MW see Hampel H
Ritchie JC see Newport DJ
Ritchie K, Jaussent I, Stewart R, Dupuy A-M, Courtet P, Ancelin M-L, Malafosse A. Association of adverse childhood environment and 5-HTTLPR genotype with late-life depression. Sept 1281–1288
Rivera SM see Bourgeois JA
Robertson-Plouch CK see Kryzhanovskaya LA
Robinson DS see Rickels K
Robinson NJ see Thakrar BT
Rochas M see Schwartz M
Rochon PA see Shulman KI
Rodríguez-Sánchez JM see Crespo-Facorro B
Rofman ES. Review of Sadock BJ, Sadock VA: *Kaplan and Sadock's Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry, 10th ed.* June 940
Rohde LA see Tramontina S
Rohde P see Vitiello B
Romero S, Birmaher B, Axelson DA, Iosif A-M, Williamson DE, Gill MK, Goldstein BI, Strober MA, Hunt J, Goldstein TR, Esposito-Smythers C, Iyengar S, Ryan ND, Keller M. Negative life events in children and adolescents with bipolar disorder. Oct 1452–1460
Rosen RC see Johannes CB
Rosenblatt LC see Meyer JM
Rosenblum A see Barry DT
Rosenheck RA see Mohamed S
Ross J see Sayers SL
Ross R see Velligan DI
Rouillon F see Goodwin GM
Roux P, Carrieri MP, Michel L, Fugon L, Marcellin F, Obadia Y, Spire B. Effect of anxiety symptoms on adherence to highly active antiretroviral therapy in HIV-infected women [letter]. Sept 1328–1329
Roy-Byrne PP. Peer review in early career: just say yes! [commentary] Nov 1602–1603
Ruedrich SL see Fletcher RJ
Ruggero CJ, Zimmerman M. Reply to Manning JS: Overdiagnosis and underdiagnosis of bipolar disorder [letter]. Jan 143–144
Ruggero CJ see Zimmerman M
Ruggiero KJ see Ford JD
Ruhrmann S see McGorry PD
Rummans TA see Rasmussen KG
Rush AJ see Husain MM; Nejtek VA
Russo PA see Johannes CB
Rüther E see Lange-Asschenfeldt C
Ryan ND see Romero S
Rycyna CC see Henin A
Ryu J see Kim B
Saavedra-Velez C, Yusim A, Anbarasan D, Lindenmayer J-P. Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review. Jan 104–112
Sachs GS see Goldberg JF
Sadak TI see Shores MM
Sadler JZ see Brandon AR
Saito M see Yasui-Furukori N
Saiz-Ruiz J see Blasco-Fontecilla H
Sajatovic M see Velligan DI
Salomon RM. Review of Fink M: *Electroconvulsive Therapy: A Guide for Professionals and Their Patients.* Mar 436
Salomon RM. Review of Shannahoff-Khalsa DS: *Psychophysiological States: The Ultradian Dynamics of Mind-Body Interactions.* Nov 1612–1613
Saltin B see Krogh J
Salvatore P, Baldessarini RJ, Tohen M, Khalsa H-MK, Sanchez-Toledo JP, Zarate CA Jr, Vieta E, Maggini C. McLean-Harvard International First-Episode Project: two-year stability of DSM-IV diagnoses in 500 first-episode psychotic disorder patients. Apr 458–466
Salzman C. Review of Jacobson SA, Pies RW, Katz IR: *Clinical Manual of Geriatric Psychopharmacology.* May 773–774
Sampson SM see Rasmussen KG
Samson JA see Teicher MH
Sanacora G. Do glutamatergic agents represent a new class of antidepressant drugs? part 1 [ASCP Corner]. Oct 1473–1474
Sanacora G. Do glutamatergic agents represent a new class of antidepressant drugs? part 2 [ASCP Corner]. Nov 1604–1605
Sanacora G. Reviewing medications for bipolar disorder: understanding the mechanisms of action. Jan e02
Sánchez P, Ojeda N, Peña J, Elizagárate E, Yoller AB, Gutiérrez M, Ezcurra J. Predictors of longitudinal changes in schizophrenia: the role of processing speed. June 888–896
Sánchez R see Murru A
Sánchez S see Díaz-Marsá M
Sanchez-Moreno J, Martinez-Aran A, Colom F, Scott J, Tabarés-Seisdedos R, Sugranyes G, Torrent C, Daban C, Benabarre A, Goikolea JM, Franco C, González-Pinto A, Ayuso-Mateos JL, Vieta E. Neurocognitive dysfunctions in euthymic bipolar patients with and without prior history of alcohol use. Aug 1120–1127
Sánchez-Moreno J see Martinez-Aran A; Scott J
Sanchez-Toledo JP see Salvatore P
Santonastaso P see Favaro A
Sarasola DR see Taragano FE
Sato Y see Yasui-Furukori N
Saville BR see Goldberg JF
Sayers SL, Farrow VA, Ross J, Oslin DW. Family problems among recently returned military veterans referred for a mental health evaluation. Feb 163–170
Schaefer D see Rapaport MH
Schaffer A see Rapoport MJ
Schene AH see Bockting CLH; ten Doesschate MC
Schiffer AA, Pelle AJ, Smith ORF, Widdershoven JW, Hendriks EH, Pedersen SS. Somatic versus cognitive symptoms of depression as predictors of all-cause mortality and health status in chronic heart failure. Dec 1667–1673
Schillinger M see Wilens TE
Schneider A, Hasan A, Hirschel S, Wilhelm C, Kohlhase J, Falkai P, Gärtner J, Steinfeld R, Wobrock T, Degner D. Novel mutation of the arylsulfatase A gene in late-onset

metachromatic leukodystrophy [letter]. Dec 1724–1725
Schneider AL, Mosier KE, Tempier RP. Switching antipsychotic medications: a 2-year chart-review study exploring patient characteristics and psychiatric service use of schizophrenia patients [letter]. June 937–939
Schnyer R see Dennehy EB
Schönknecht P see Hampel H
Schooler NR see Weiden PJ
Schottenfeld RS see Barry DT
Schröder J see Hampel H
Schultze-Lutter F see McGorry PD
Schwalberg M see Klass ET
Schwartz M, Kormilachev M, Kushnir M, Weller B, Rochas M, Toubi E. Lupus anticoagulant and anticardiolipin antibodies in serum of patients treated with risperidone [letter]. May 769–771
Scott J, Colom F, Popova E, Benabarre A, Cruz N, Valenti M, Goikolea JM, Sánchez-Moreno J, Asenjo MA, Vieta E. Long-term mental health resource utilization and cost of care following group psychoeducation or unstructured group support for bipolar disorders: a cost-benefit analysis. Mar 378–386
Scott J see Martinez-Aran A; Sánchez-Moreno J; Velligan DI
Scrimin S see Moscardino U
Segal K see Simeon D
Segal ZV see Levitan RD
Segraves RT. Review of IsHak WW: *The Guidebook of Sexual Medicine.* June 941–942
Serrano CM see Taragano FE
Severs J see Nakamura M
Shajahan P, Keith S, Majjiga C, Murphy J, MacRae A, Bashir M, Taylor M. Comparing the effectiveness of aripiprazole and quetiapine in schizophrenia and related psychoses: a naturalistic, retrospective chart review study. May 692–698
Shalev AY see Zohar J
Shammi C see Sockalingam S
Shapiro CM see Shen J
Shapiro GK see Shen J
Sheffrin M, Driscoll HC, Lenze EJ, Mulsant BH, Pollock BG, Miller MD, Butters MA, Dew MA, Reynolds CF III. Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: getting to remission. Feb 208–213
Shekher M see Soto EC
Shelton RC. Long-term management of depression: tips for adjusting the treatment plan as the patient's needs change. Suppl 6, 32–37
Shelton RC. St John's wort (*Hypericum perforatum*) in major depression. Suppl 5, 23–27
Shen J, Moller HJ, Wang X, Chung SA, Shapiro GK, Li X, Shapiro CM. Mirtazapine, a sedating antidepressant, and improved driving safety in patients with major depressive disorder: a prospective, randomized trial of 28 patients. Mar 370–377
Shifren JL see Johannes CB
Shin M-S see Kim B-N
Shivakumar G see Brandon AR; Dennehy EB
Shore JH. Review of Helzer JE, Kraemer HC, Krueger RF, Wittchen H-U, Sirovatka PJ, Regier DA (eds): *Dimensional Approaches in Diagnostic Classification: Refining the Research Agenda for DSM-V.* July 1061
Shores MM, Kivlahan DR, Sadak TI, Li EJ, Matsumoto AM. Randomized, double-blind, placebo-controlled study of testosterone treatment in hypogonadal older men with subthreshold depression (dysthymia or minor depression). July 1009–1016
Shulman KI, Fischer HD, Herrmann N, Huo CY, Anderson GM, Rochon PA. Current prescription patterns and safety profile of irreversible monoamine oxidase inhibitors: a population-based cohort study of older adults. Dec 1681–1686
Shulman KI see Rapoport MJ
Siddique H, Hynan LS, Weiner MF. Effect of a serotonin reuptake inhibitor on irritability, apathy, and psychotic symptoms in patients with Alzheimer's disease. June 915–918
Silva SG see Vitiello B
Silverman MM see Fawcett JA
Simeon D, Kozin DS, Segal K, Lerch B. Is depersonalization disorder initiated by illicit drug use any different? a survey of 394 adults. Oct 1358–1364
Simeon D see Cunill R
Simon GE. Practical lessons from effectiveness trials of care management and psychoeducation for bipolar disorder. Aug e28
Simon NM. Generalized anxiety disorder and psychiatric comorbidities such as depression, bipolar disorder, and substance abuse. Suppl 2, 10–14
Simon NM, Otto MW, Worthington JJ, Hoge EA, Thompson EH, LeBeau RT, Moshier SJ, Zalta AK, Pollack MH. Next-step strategies for panic disorder refractory to initial pharmacotherapy: a 3-phase randomized clinical trial. Nov 1563–1570
Simon V, van Winkel R, De Hert M. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? a literature review. July 1041–1050
Sit DKY see Bodnar LM
Slomowitz M. Review of Heru AM, Drury LM: *Working With Families of Psychiatric Inpatients: A Guide for Clinicians.* May 774
Smid GE, Mooren TTM, van der Mast RC, Gersons BPR, Kleber RJ. Delayed posttraumatic stress disorder: systematic review, meta-analysis, and meta–regression analysis of prospective studies. Nov 1572–1582
Smith J see Mischoulon D
Smith ORF see Schiffer AA
Smith RC, Lindenmayer J-P, Davis JM, Kelly E, Viviano TF, Cornwell J, Hu Q, Khan A, Vaidhyanathaswamy S. Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study. Nov 1501–1513
Snow DE see Dennehy EB
Snyder PJ see Stonnington CM
Soares CN, Kornstein SG, Thase ME, Jiang Q, Guico-Pabia CJ. Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: a pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials. Oct 1365–1371
Soares CN, Steiner M. Perinatal depression: searching for specific tools for a closer look at this window [commentary]. Sept 1317–1318
Sockalingam S, Shammi C, Remington G. Treatment of clozapine-induced hypersalivation with ipratropium bromide: a randomized, double-blind, placebo-controlled crossover study. Aug 1114–1119
Soczynska JK see Goldstein BI
Solà R see Castellvi P
Solomon DA. Melancholia as a useful subtype of major depression [letter]. Sept 1326
Solomon DN. Do we scare because we care? [commentary] Sept 1316–1317
Solomon Z, Horesh D, Ein-Dor T. Longitudinal course of posttraumatic stress disorder symptom clusters among war veterans. June 837–843
Solorzano E see Zisook S
Sonawalla SB see Mischoulon D
Soto EC, Frederickson AM, Trivedi H, Le A, Eugene MC, Shekher M,

Weiskopf M, Allen-Dicker K, Dicker R, Fornari V, Correll CU. Frequency and correlates of inappropriate pediatric psychiatric emergency room visits. Aug 1164–1177
Spalding RT. Review of Gurman AS (ed): *Clinical Handbook of Couple Therapy, 4th ed.* Oct 1483
Spann ME see Perahia DGS
Sparshatt A see Taylor DM
Spencer TJ see Wilens TE
Spiliotacopoulos D see Gleeson JFM
Spinhoven P see Bockting CLH
Spire B see Roux P
Stahl SM. Combining antidepressant therapies from the initiation of treatment: a paradigm shift for major depression [Brainstorms]. Nov 1493–1494
Stahl SM. Epigenetics and methylomics in psychiatry [Brainstorms]. Sept 1204–1205
Stahl SM. Norepinephrine and dopamine regulate signals and noise in the prefrontal cortex. [Brainstorms]. May 617–618
Stahl SM. Prefrontal cortex is out of tune in attention-deficit/hyperactivity disorder [Brainstorms]. July 950–951
Stahl SM. Vasomotor symptoms and depression in women, part 1: role of vasomotor symptoms in signaling the onset or relapse of a major depressive episode [Brainstorms]. Jan 11–12
Stahl SM. Vasomotor symptoms and depression in women, part 2: treatments that cause remission and prevent relapses of major depressive episodes overlap with treatments for vasomotor symptoms [Brainstorms]. Mar 310–311
Stahl SM see Mischoulon D
Star K see Karlsson J
Stassen HH see Szegedi A
Stauffer V see Lindenmayer J-P
Stauffer VL see Kane JM
Stavrakaki C see Fletcher RJ
Stein DJ see Fawcett JA; Matsunaga H
Stein MB. Neurobiology of generalized anxiety disorder. Suppl 2, 15–19
Steinberg HR. Review of Barlow DH (ed): *Clinical Handbook of Psychological Disorders: A Step-by-Step Treatment Manual, 4th ed.* Nov 1612
Steiner M see Soares CN
Steinfeld R see Schneider A
Stensland MD, Ascher-Svanum H, Lawson AH, Conley RR. Overestimating the prevalence of subtherapeutic dosing of atypical antipsychotics [letter with reply]. Aug 1189–1191
Stern R. Review of PDM Task Force: *Psychodynamic Diagnostic Manual (PDM).* Oct 1483–1485
Stern TA see Gross AF
Stewart R see Ritchie K
Stonnington CM, Snyder PJ, Hentz JG, Reiman EM, Caselli RJ. Double-blind crossover study of the cognitive effects of lorazepam in healthy apolipoprotein E (APOE)-ε4 carriers. Oct 1379–1384
Stowe ZN see Newport DJ
Strain JJ. Review of Guerrero APS, Piasecki M (eds): *Problem-Based Behavioral Science and Psychiatry.* Aug 1195
Strakowski SM. Review of Sajatovic M, Blow FC (eds): *Bipolar Disorder in Later Life.* Dec 1731–1732
Strauss R see Deisenhammer EA
Stravogiannis A see Fu-I L
Streiner DL see Rapoport MJ
Strober MA see Romero S
Strøm M, Mortensen EL, Halldorson TI, Østerdal ML, Olsen SF. Leisure-time physical activity in pregnancy and risk of postpartum depression: a prospective study in a large national birth cohort. Dec 1707–1714
Stubbe DE see Ebert MH
Su K-P see Chang H-C
Su YA see Chen JX
Subirà S see Castellvi P
Subramaniam M see Verma SK
Sugar CA see Altshuler LL
Sugranyes G see Sanchez-Moreno J
Sun W see Kane JM
Sunakawa A see Weiden PJ
Suominen K, Haukka J, Valtonen HM, Lönnqvist J. Outcome of patients with major depressive disorder after serious suicide attempt. Oct 1372–1378
Suppes T see Altshuler LL; Dennehy EB; Goldberg JF
Sureddi S see Dennehy EB
Suri R, Altshuler LL. No decision is without risk [commentary]. Sept 1319–1320
Surman CBH, Adamson JJ, Petty C, Biederman J, Kenealy DC, Levine M, Mick E, Faraone SV. Association between attention-deficit/hyperactivity disorder and sleep impairment in adulthood: evidence from a large controlled study. Nov 1523–1529
Sussman M see Menzin J
Suzuki T see Nakajima S
Swanson RD see Reger MA
Szamosi J see Bauer M
Szegedi A, Jansen WT, van Willigenburg APP, van der Meulen E, Stassen HH, Thase ME. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. Mar 344–353
Tabarés-Seisdedos R, Gómez-Beneyto M, Haro J-M, González-Pinto A, Vieta E. Importance of negative comorbidity [letter with reply]. Aug 1191–1192
Tabarés-Seisdedos R see Martinez-Aran A; Sanchez-Moreno J
Tafesse E see Menzin J
Tampi RR. Review of Jacoby R, Oppenheimer C, Dening T, Thomas A (eds): *Oxford Textbook of Old Age Psychiatry* (4th edition of formerly named *Psychiatry in the Elderly*). Nov 1611–1612
Tang C-H see Chang H-C
Tang SW see Lee P
Taragano FE, Allegri RF, Krupitzki H, Sarasola DR, Serrano CM, Loñ L, Lyketsos CG. Mild behavioral impairment and risk of dementia: a prospective cohort study of 358 patients. Apr 584–592
Tardiff K see Abrams RC
Tariot PN, Aisen PS. Can lithium or valproate untie tangles in Alzheimer's disease? [commentary] June 919–921
Tassone F see Bourgeois JA
Taylor DM, Fischetti C, Sparshatt A, Thomas A, Bishara D, Corņelius V. Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice. Feb 196–200
Taylor M see Shajahan P
Teicher MH, Samson JA, Polcari A, Andersen SL. Length of time between onset of childhood sexual abuse and emergence of depression in a young adult sample: a retrospective clinical report. May 684–691
Tempier RP see Schneider AL
Tenconi E see Favaro A
ten Doesschate MC, Bockting CLH, Koeter MWJ, Schene AH. Predictors of nonadherence to continuation and maintenance antidepressant medication in patients with remitted recurrent depression. Jan 63–69
Thakrar BT, Robinson NJ. Isotretinoin and the risk of depression [letter with reply]. Oct 1475–1476
't Hart-Kerkhoffs LA, Jansen LM, Doreleijers TA, Vermeiren R, Minderaa RB, Hartman CA. Autism spectrum disorder symptoms in juvenile suspects of sex offenses. Feb 266–272
Thase ME. Diagnosis and treatment of a major depressive episode. Oct e37
Thase ME. Evaluating atypical antipsychotics in the treatment of refractory depression. May e14
Thase ME. Newer medications for complicated depression. Sept e33

Thase ME. Pharmacotherapeutic treatment strategies for antidepressant nonresponse. Nov e42
Thase ME. Update on partial response in depression. Suppl 6, 4–9
Thase ME see Goldberg JF; Kocsis JH; Perahia DGS; Szegedi A; Soares CN; Trivedi MH
Thomas A see Taylor DM
Thompson EH see Simon NM
Thompson T. Review of Chawarska K, Klin A, Volkmar FR (eds): *Autism Spectrum Disorders in Infants and Toddlers: Diagnosis, Assessment, and Treatment*. Sept 1330
Tiemeier H see van den Berg JF
Timmermans MA see van der Loos MLM
Tohen M. In memoriam: Franco Benazzi, MD, 1957–2009. Nov 1522
Tohen M see Benazzi F; Houston JP; Salvatore P
Tolliver BK see Gao K
Tong M-L see Oskooilar N
Torrent C see Martinez-Aran A; Sanchez-Moreno J
Toubi E see Schwartz M
Tragl K-H see Mossaheb N
Tramontina S, Zeni CP, Ketzer CR, Pheula GF, Narvaez J, Rohde LA. Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial. May 756–764
Trivedi H see Soto EC
Trivedi MH. Tools and strategies for ongoing assessment of depression: a measurement-based approach to remission. Suppl 6, 26–31
Trivedi MH. Treating depression to full remission. Jan e01
Trivedi MH. Treating partial responders to antidepressant treatment. Sept e31
Trivedi MH, Thase ME, Osuntokun O, Henley DB, Case M, Watson SB, Campbell GM, Corya SA. Integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression. Mar 387–396
Trivedi MH see Husain MM
Tsai S-J see Chang H-C
Tschoner A, Engl J, Rettenbacher MA, Kaser S, Ott HW, Fleischhacker WW, Patsch JR, Ebenbichler CF. Is second-generation antipsychotic–induced hyperprolactinemia due to biologically active prolactin or to biologically inactive macroprolactin? results from a prospective study [letter]. Feb 293–294
Tulen JHM see van den Berg JF
Turecki G see Diaconu G
Turkington D see Malik N
Tyrka AR see Philip NS
Tzanis E see Liebowitz MR
Uchida H, Mamo DC, Mulsant BH, Pollock BG, Kapur S. Increased antipsychotic sensitivity in elderly patients: evidence and mechanisms. Mar 397–405
Uchida H see Nakajima S
Uebelacker LA see Gaudiano BA
Uhde TW see Flosnik DL; Moore GJ
Unuigbe FE see McCue RE
Vaccarino AL see Laska EM
Vaidhyanathaswamy S see Smith RC
Valenstein M see Ilgen MA
Valenti M see Scott J
Valtonen HM see Suominen K
Valuck RJ, Orton HD, Libby AM. Antidepressant discontinuation and risk of suicide attempt: a retrospective, nested case-control study. Aug 1069–1077
van den Berg JF, Luijendijk HJ, Tulen JHM, Hofman A, Neven AK, Tiemeier H. Sleep in depression and anxiety disorders: a population-based study of elderly persons. Aug 1105–1113
Vanderburg DG, Batzar E, Fogel I, Kremer CME. Pooled analysis of suicidality in double-blind, placebo-controlled studies of sertraline in adults. May 674–683
van der Loos MLM, Mulder PGH, Hartong EGThM, Blom MBJ, Vergouwen AC, de Keyzer HJUEM, Notten PJH, Luteijn ML, Timmermans MA, Vieta E, Nolen WA, for the LamLit Study Group. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. Feb 223–231
van der Mast RC see Smid GE
van der Meulen E see Szegedi A
van der Velden PG, Yzermans JC. Long-term effects of the terrorist attack in Beslan on adolescent survivors [letter with reply]. June 934
van Oppen P see Cuijpers P; Wiersma JE
van Schaik DJF see Wiersma JE
van Straten A see Cuijpers P
van Willigenburg APP see Szegedi A
van Winkel R see Simon V
Vasar V see Maron E
Vázquez-Barquero JL see Crespo-Facorro B
Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, Docherty JP. Expert Consensus Guideline Series: Adherence Problems in Patients With Serious and Persistent Mental Illness. Suppl 4, 3–46
Vergouwen AC see van der Loos MLM
Verma SK, Subramaniam M, Liew A, Poon LY. Metabolic risk factors in drug-naive patients with first-episode psychosis. July 997–1000
Vermeiren R see 't Hart-Kerkhoffs LA
Versavel M see Gandelman K
Versiani M see Keck PE Jr
Vester-Blokland E see Kane JM
Vetró Á see Baji I
Vieta E see Martinez-Aran A; Murru A; Salvatore P; Sanchez-Moreno J; Scott J; Tabarés-Seisdedos R; van der Loos MLM
Vingilis E see Rapoport MJ
Vitiello B, Silva SG, Rohde P, Kratochvil CJ, Kennard BD, Reinecke MA, Mayes TL, Posner K, May DE, March JS. Suicidal events in the Treatment for Adolescents With Depression Study (TADS). May 741–747
Viviano TF see Smith RC
Volavka J, Citrome L. All antipsychotics are equal, but some are more equal than others [ASCP Corner]. Mar 429–430
Volavka J see Lindenmayer J-P
Volpi S, Potkin SG, Malhotra AK, Licamele L, Lavedan C. Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. June 801–809
Vulink NCC, Denys D, Fluitman SBAHA, Meinardi JCM, Westenberg HGM. Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients. July 1001–1008
Wade D see Gleeson JFM
Wagner KD. Life events, medical comorbidity, and somatic symptoms in pediatric mood disorders [introduction]. Oct 1439–1440
Wagner KD. Medication and diagnostic issues [introduction]. Feb 238–239
Wagner KD. Predictors, criteria, and treatment response [introduction]. May 730–731
Wagner KD. Trauma, emergency room visits, and cognition [introduction]. Aug 1146–1147
Waheed R see McCue RE
Walker DJ see Perahia DGS
Walker JS. Review of Folensbee RW: *The Neuroscience of Psychological Therapies*. May 773
Wallerstedt SM see Karlsson J
Walsh JP see Freudenreich O
Wance D see Lindenmayer J-P
Wang F see Perahia DGS
Wang N see Chen JX
Wang SL see Chen JX
Wang W see Benazzi F
Wang X see Shen J
Wang Y-P see Fu-I L

Wang-Weigand S see Richardson GS
Warrington L see Keck PE Jr
Watanabe K see Nakajima S
Watson SB see Kane JM; Trivedi MH
Weedon JC see Weiden PJ
Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa A, Goldfinger SM. Randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. Oct 1397–1406
Weiden PJ see Nasrallah HA; Velligan DI
Weinberger DR see Nasrallah HA
Weiner MF see Siddique H
Weinstein DD. Review of Nace EP, Tinsley JA: *Patients With Substance Abuse Problems: Effective Identification, Diagnosis, and Treatment.* Apr 608
Weisberg RB. Overview of generalized anxiety disorder: epidemiology, presentation, and course. Suppl 2, 4–9
Weiskopf M see Soto EC
Weisler RH see Adler LA
Weiss AP, Guidi J, Fava M. Closing the efficacy-effectiveness gap: translating both the what and the how from randomized controlled trials to clinical practice [commentary]. Apr 446–449
Weiss EM see Deisenhammer EA
Weiss RD see Jaffee WB
Weissgram S see Mossaheb N
Weissman S. Review of Ebert MH, Loosen PT, Nurcombe B, Leckman JF (eds): *Current Diagnosis & Treatment: Psychiatry, 2nd ed.* Sept 1330–1331
Weissman Z see Zohar J
Weller B see Schwartz M
Westenberg HGM see Vulink NCC
Westerberg D see Wilens TE
Whalen H see Rickels K
Whitehead R see Meyer JM
Whiteley LB see Philip NS
Widdershoven JW see Schiffer AA
Wiechers IR see Gross AF
Wiersma JE, Hovens JGFM, van Oppen P, Giltay EJ, van Schaik DJF, Beekman ATF, Penninx BWJH. Importance of childhood trauma and childhood life events for chronicity of depression in adults. July 983–989
Wilcox CS see Oskooilar N
Wilens TE, Biederman J, Faraone SV, Martelon M, Westerberg D, Spencer TJ. Presenting ADHD symptoms, subtypes, and comorbid disorders in clinically referred adults with ADHD. Nov 1557–1562
Wilens TE, Martelon MK, Kruesi MJP, Parcell T, Westerberg D, Schillinger M, Gignac M, Biederman J. Does conduct disorder mediate the development of substance use disorders in adolescents with bipolar disorder? a case-control family study. Feb 259–265
Wilhelm C see Schneider A
Williamson DE see Romero S
Wingo AP, Wingo TS, Harvey PD, Baldessarini RJ. Effects of lithium on cognitive performance: a meta-analysis. Nov 1588–1597
Wingo TS see Wingo AP
Winstead DK see Ebert MH
Wisdom JP Hartung DM
Wise TN. Review of McHugh PR: *Try to Remember: Psychiatry's Clash Over Meaning, Memory, and Mind.* Oct 1481–1482
Wise TN. Review of Mendelson SD: *Metabolic Syndrome and Psychiatric Illness: Interactions, Pathophysiology, Assessment and Treatment.* Jan 146–147
Wisner KL see Bodnar LM; Lanza di Scalea T
Wisniewski SR see Husain MM
Wobrock T Schneider A
Wooderson S see Fekadu A
Wooderson SC see Fekadu A
Woodward AT see Perron BE
Worthington JJ see Simon NM
Wouters LF see Bockting CLH
Wozniak J see Biederman J; Henin A
Xu W see Kane JM; Kryzhanovskaya LA
Yang FD see Chen JX
Yasui-Furukori N, Sato Y, Furukori H, Saito M, Nakagami T, Kaneko S. Glucose metabolism in Japanese schizophrenia patients treated with risperidone or olanzapine. Jan 95–100
Yen F-C see Chang H-C
Yip PSF see Fu K-w
Yoller AB see Sánchez P
Young AH. Bipolar disorder: diagnostic conundrums and associated comorbidities. Aug e26
Young D see Zimmerman M
Young E see Husain MM
Young JQ, Nelson JC. Reconceptualizing medication management: implications for training and clinical practice [ASCP Corner]. Dec 1722–1723
Yuan P see Machado-Vieira R
Yun M-J see Kim B-N
Yung AR see McGorry PD
Yusim A see Saavedra-Velez C
Yzermans JC see van der Velden PG
Zach EB see Newport DJ
Zajac-Benitez C see Moore GJ
Zalta AK see Simon NM
Zammit G see Richardson GS
Zarate CA Jr see Machado-Vieira R; Salvatore P
Zeber JE see Evans-Lacko SE
Zehetmayer S see Mossaheb N
Zeni CP see Tramontina S
Zernig G see Chenu F
Zhang J see Richardson GS
Zhang M see Lee P
Zhang XY see Chen JX
Zill P see Hennings A
Zimmerman M, Ruggero CJ, Chelminski I, Young D. Reply to Ghaemi SN: Reliability, not overdiagnosis [letter]. Apr 603–604
Zimmerman M see Ruggero CJ
ZIP-IIG-79 Study Group see Díaz-Marsá M
Zisook S, Kasckow JW, Golshan S, Fellows I, Solorzano E, Lehman D, Mohamed S, Jeste DV. Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: a randomized controlled trial. Apr 562–571
Zivin K see Ilgen MA
Zohar J, Fostick L, Cohen A, Bleich A, Dolfin D, Weissman Z, Doron M, Kaplan Z, Klein E, Shalev AY, Israeli Consortium on PTSD. Risk factors for the development of posttraumatic stress disorder following combat trauma: a semiprospective study. Dec 1629–1635